0001493152-19-012175.txt : 20190813 0001493152-19-012175.hdr.sgml : 20190813 20190813143117 ACCESSION NUMBER: 0001493152-19-012175 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: One World Pharma, Inc. CENTRAL INDEX KEY: 0001622244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611744826 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-200529 FILM NUMBER: 191019873 BUSINESS ADDRESS: STREET 1: 3471 WEST OQUENDO ROAD, SUITE 301 CITY: LAS VEGAS STATE: NV ZIP: 89118 BUSINESS PHONE: 7026050605 MAIL ADDRESS: STREET 1: 3471 WEST OQUENDO ROAD, SUITE 301 CITY: LAS VEGAS STATE: NV ZIP: 89118 FORMER COMPANY: FORMER CONFORMED NAME: PUNTO GROUP, CORP. DATE OF NAME CHANGE: 20141014 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 333-200529

ONE WORLD PHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada		61-1744826
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3471 W. Oquendo Road, Suite 301, Las Vegas, NV		89118
(Address of principal executive offices)		(zip code)

(800) 605-3210

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Smaller reporting company	[X]
		Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

The number of shares of registrant’s common stock outstanding as of August 12, 2019 was 41,466,899.

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2019 (Unaudited) and December 31, 2018	3
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2019 and the Three Months Ended June 30, 2018 and the Period from Inception (March 27, 2018) to June 30, 2018 (Unaudited)	4
	Consolidated Statement of Stockholders’ Equity for the Six Months Ended June 30, 2019 (Unaudited) and the Year Ended December 31, 2018	5
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2019 and the Period from Inception (March 27, 2018) to June 30, 2018 (Unaudited)	6
	Notes to the Condensed Consolidated Financial Statements (Unaudited)	7
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	23
ITEM 4.	CONTROLS AND PROCEDURES	24
PART II - OTHER INFORMATION
ITEM 1.	Legal Proceedings	25
ITEM 1A.	RISK FACTORS	25
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	25
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	25
ITEM 4.	MINE SAFETY DISCLOSURES	25
ITEM 5.	OTHER INFORMATION
ITEM 6.	EXHIBITS	26
	SIGNATURES	27

PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2019			December 31, 2018
		(Unaudited)
Assets

Current assets:
Cash	$	212,385		$	125,846
Other current assets		136,779			35,344
Inventory		24,978			-
Total current assets		374,142			161,190

Right-of-use asset		258,754			-
Security deposits		69,542			-
Fixed assets, net		713,932			356,439

Total Assets	$	1,416,370		$	517,629

Liabilities and Stockholders' Equity (Deficit)

Current liabilities:
Accounts payable	$	175,129		$	121,194
Accrued expenses		99,107			34,425
Current portion of lease liability		38,561			-
Convertible note payable		300,000			300,000
Advances from shareholders		307,141			514,141
Notes payable		200,000			200,000
Total current liabilities		1,119,938			1,169,760

Long-term lease liability		222,358			-

Total Liabilities		1,342,296			1,169,760

Stockholders' Equity (Deficit):
Common stock, $0.001 par value, 75,000,000 shares authorized; 39,922,899 and 34,291,905 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively		39,923			34,292
Additional paid-in capital		4,503,966			1,278,352
Subscriptions receivable, consisting of 6,012,500 shares at December 31, 2018		-			(602	)
Accumulated other comprehensive loss		138,911			(4,090	)
Accumulated (deficit)		(4,608,726	)		(1,959,982	)
		74,074			(652,030	)
Noncontrolling Interest		-			(101	)
Total Stockholders' Equity (Deficit)		74,074			(652,131	)

Total Liabilities and Stockholders' Equity (Deficit)	$	1,416,370		$	517,629

See accompanying notes to financial statements.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended			From Inception (March 27, 2018) to
	2019			2018			June 30, 2019			June 30, 2018

Revenue:	$	-		$	-		$	-		$	-

Operating expenses:
General and administrative		565,167			124,840			1,044,787			124,840
Professional fees		741,542			156,977			1,444,422			156,977
Total operating expenses		1,306,709			281,817			2,489,209			281,817

Operating loss		(1,306,709	)		(281,817	)		(2,489,209	)		(281,817	)

Other income (expense):
Loss on disposal of assets		(4,087	)		-			(4,087	)		-
Interest income		147			-			248			-
Interest expense		(14,579	)		(1,801	)		(155,696	)		(1,801	)
Total other expense		(18,519	)		(1,801	)		(159,535	)		(1,801	)

Net loss	$	(1,325,228	)	$	(283,618	)	$	(2,648,744	)	$	(283,618	)

Other comprehensive loss:
Gain on foreign currency translation	$	151,288		$	-		$	143,001		$	35,402

Net other comprehensive loss	$	(1,173,940	)	$	(283,618	)	$	(2,505,743	)	$	(248,216	)

Weighted average number of common shares outstanding - basic and fully diluted		39,922,899			29,777,996			38,779,975			29,410,501

Net loss per share - basic and fully diluted	$	(0.03	)	$	(0.01	)	$	(0.06	)	$	(0.01	)

See accompanying notes to financial statements.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

													Accumulated									Total
							Additional						Other									Stockholders'
	Common Stock						Paid-In			Subscriptions			Comprehensive			Accumulated			Noncontrolling			Equity
	Shares			Amount			Capital			Receivable			Income (Loss)			Deficit			Interest			(Deficit)

Balance, March 27, 2018		-		$	-		$	-		$	-		$	-		$	-		$	-		$	-

Consolidation of One World Pharma, Inc.		-			-			(349,420	)		-			-			-			-			(349,420	)

Common stock sold for cash		23,411,905			23,412			978,703			(602	)		-			-			-			1,001,513

Common stock issued for services		680,000			680			284,920			-			-			-			-			285,600

Common stock issued for purchase of One World Pharma S.A.S.		10,200,000			10,200			152,709			-			-			-			-			162,909

Contributed capital		-			-			136,440			-			-			-			-			136,440

Beneficial conversion feature on convertible note		-			-			75,000			-			-			-			-			75,000

Loss on foreign currency translation		-			-			-			-			(4,090	)		-			-			(4,090	)

Net loss		-			-			-			-			-			(1,959,982	)		(101	)		(1,960,083	)

Balance, December 31, 2018		34,291,905		$	34,292		$	1,278,352		$	(602	)	$	(4,090	)	$	(1,959,982	)	$	(101	)	$	(652,131	)

Cash received on subscriptions receivable of OWP Ventures, Inc.		-			-			-			602			-			-			-			602

Common stock of OWP Ventures, Inc. sold for cash		3,900,000			3,900			1,946,100			-			-			-			-			1,950,000

Issuance of common stock of OWP Ventures, Inc. on debt conversion		1,253,493			1,253			500,144			-			-			-			-			501,397

Common stock issued for services, OWP Ventures, Inc.		30,000			30			14,970			-			-			-			-			15,000

Amortization of common stock options issued for services, OWP Ventures, Inc.		-			-			88,297			-			-			-			-			88,297

Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1)		1,322,501			1,323			(10,730	)		-			-			-			101			(9,306	)

Common stock cancelled pursuant to merger with OWP Ventures, Inc.		(875,000	)		(875	)		875			-			-			-			-			-

Amortization of common stock options issued for services		-			-			560,958			-			-			-			-			560,958

Beneficial conversion feature on convertible note		-			-			125,000			-			-			-			-			125,000

Gain on foreign currency translation		-			-			-			-			143,001			-			-			143,001

Net loss		-			-			-			-			-			(2,648,744	)		-			(2,648,744	)

Balance, June 30, 2019 (Unaudited)		39,922,899		$	39,923		$	4,503,966		$	-		$	138,911		$	(4,608,726	)	$	-		$	74,074

See accompanying notes to financial statements.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

	For the Six			From Inception
	Months Ended			(March 27, 2018) to
	June 30, 2019			June 30, 2018
Cash flows from operating activities
Net loss	$	(2,648,744	)	$	(283,618	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		5,005			103
Loss on disposal of fixed assets		4,087
Debt discounts		125,000			-
Stock-based compensation		15,000			-
Amortization of options issued for services		649,255			-
Decrease (increase) in assets:
Other current assets		(110,741	)		-
Inventory		(24,978	)		-
Right-of-use assets		(258,754	)		-
Security deposits		(69,542	)		(13,092	)
Increase (decrease) in liabilities:
Accounts payable		53,935			7,957
Accrued expenses		66,079			2,753
Lease liability		260,919			-
Net cash used in operating activities		(1,933,479	)		(285,897	)

Cash flows from investing activities
Purchase of fixed assets		(366,585	)		(11,585	)
Net cash used in investing activities		(366,585	)		(11,585	)

Cash flows from financing activities
Proceeds from convertible note payable		500,000			-
Proceeds from shareholders		-			207,000
Repayment of advances from shareholders		(207,000	)		-
Proceeds from subscriptions receivable		602			-
Proceeds from sale of common stock		1,950,000			500,000
Net cash provided by financing activities		2,243,602			707,000

Effect of exchange rate changes on cash		143,001			35,402

Net increase in cash		86,539			444,920
Cash - beginning		125,846			-
Cash - ending	$	212,385		$	444,920

Supplemental disclosures:
Interest paid	$	14,965		$	-
Income taxes paid	$	-		$	-

Non-cash investing and financing transactions:
Fair value of net assets acquired in merger	$	9,306		$	-
Value of shares issued for conversion of debt	$	501,397		$	-
Beneficial conversion feature	$	125,000		$	-

See accompanying notes to financial statements.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

One World Pharma, Inc. (formerly Punto Group, Corp.) was incorporated in Nevada on September 2, 2014. On February 21, 2019, One World Pharma, Inc. (“One World Pharma,” the “Company,” “we,” “our” or “us”) entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma SAS, a Colombian company (“OWP Colombia”). Pursuant to the Merger Agreement, we acquired OWP Ventures (and indirectly, OWP Colombia) by the merger of OWP Merger Subsidiary with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary (the “Merger”). As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors. The Company’s headquarters are located in Las Vegas, Nevada, and all of its customers are expected to be outside of the United States. On January 10, 2019, the Company changed its name from Punto Group, Corp. to One World Pharma, Inc.

OWP Ventures is a holding company formed in Delaware on March 27, 2018 to enter and support the cannabis industry, and on May 30, 2018, it acquired OWP Colombia. OWP Colombia is a licensed cannabis cultivation, production and distribution (export) company located in Popayán, Colombia (nearest major city is Cali). We plan to be a producer of raw cannabis and hemp plant ingredients for both medical and industrial uses across the globe. We have received licenses to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes. Specifically, we are one of the only companies in Colombia to receive seed, cultivation, extraction and export licenses from the Colombian government. Currently, we own approximately 30 acres and have a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we have entered into agreements with local farming co-operatives that include small farmers and indigenous tribe members, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We planted our first crop of cannabis in 2018, which we began harvesting in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced. To date, we have not yet generated any revenues from our activities.

The Merger was accounted for as a reverse merger (recapitalization) with OWP Ventures deemed to be the accounting acquirer. Accordingly, the financial statements included in this Quarterly Report on Form 10-Q reflect the historical operations of OWP Ventures and its wholly-owned subsidiary OWP SAS prior to the Merger, and that of the combined company following the Merger. The historical financial information for One World Pharma, Inc. (formerly Punto Group Corp.) prior to the Merger has been omitted.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated.

The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and Current Report on Form 8-K with respect to the Merger originally filed with the SEC on February 25, 2019, as amended and restated on July 12, 2019. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K and Current Report on Form 8-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:

	State of
Name of Entity	Incorporation	Relationship
One World Pharma, Inc.⁽¹⁾	Nevada	Parent
OWP Ventures, Inc.⁽²⁾	Delaware	Subsidiary
One World Pharma S.A.S.⁽³⁾	Colombia	Subsidiary

⁽¹⁾Holding company in the form of a corporation.

⁽²⁾Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.

⁽³⁾Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogotá on July 18, 2017. Its headquarters are located in Bogotá.

The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. The Company's headquarters are located in Las Vegas, Nevada and substantially all of its production efforts are within Popayán, Colombia.

Foreign Currency Translation

The functional currency of the Company is Columbian Peso (COP). The Company has maintained its financial statements using the functional currency, and translated those financial statements to the US Dollar (USD) throughout this report. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods.

Comprehensive Income

The Company has adopted ASC 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Segment Reporting

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

Fair Value of Financial Instruments

Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short term nature of the instruments.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, cash on deposit with various financial institutions in Columbia, and all highly-liquid investments with original maturities of three months or less at the time of purchase. We have not held any cash equivalents to date.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Cash in Excess of FDIC Insured Limits

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. The Company didn’t have any amounts in excess of FDIC insured limits at June 30, 2019, and has not experienced any losses in such accounts.

Revenue Recognition

The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of commercial sales of products, licensing agreements and contracts. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition.

There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the six months ended June 30, 2019, or the year ended December 31, 2018.

Inventory

Inventories are stated at the lower of cost or market. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our cannabis products consist of cannabis flower grown in-house, along with produced extracts.

Stock-Based Compensation

The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty's performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.

Basic and Diluted Loss Per Share

The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its financial statements.

In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. The Company is currently in the process of evaluating the impact of adoption on its financial statements.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its financial statements.

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

The new standard became effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company adopted the new standard on January 1, 2019 using the modified retrospective transition approach as of the effective date of the initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.

The most significant effects of the adoption of the new standard relate to the recognition of new ROU assets and lease labilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities.

The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has also elected the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities, for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and non-lease components for its leases. The new standard did not have a material impact.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted the new standard to be effective upon inception. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, adoption does not have a material impact on our financial position, results of operations, or cash flows. Related disclosures have been expanded in line with the requirements of the standard.

There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 2 –Going Concern

As shown in the accompanying condensed consolidated financial statements as of June 30, 2019, the Company has cash on hand of $212,385, a working capital deficit of $745,796 and an accumulated deficit of $4,608,726, and the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing its cannabis cultivation activities and expects to begin revenue generating export operations in the first quarter of 2020. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

The condensed consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 3 – Reverse Merger

On February 21, 2019, One World Pharma, Inc. entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, which is the parent company of OWP Colombia. Pursuant to the Merger Agreement, we acquired OWP Ventures (and indirectly, OWP Colombia) by the merger of OWP Merger Subsidiary with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary. As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors.

Note 4 – Related Party Transactions

Repayment and Exchanges of Advances from Shareholders

A total of $207,000 of demand notes owed to our CEO was repaid over various dates from March of 2019 through May of 2019.

On various dates between October 25, 2018 and November 23, 2018, our CEO advanced funds to the Company totaling $307,141 under short-term unsecured demand loans, bearing interest at 6% per annum. On February 13, 2019, these promissory notes were exchanged for an amended and restated promissory note in the principal amount of $307,141 that bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 5 – Fair Value of Financial Instruments

Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.

The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:

	Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

	Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

	Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheet as of June 30, 2019 and December 31, 2018, respectively:

	Fair Value Measurements at June 30, 2019
	Level 1		Level 2			Level 3
Assets
Cash	$	212,385	$	-		$	-
Right-of-use asset		-		258,754			-
Total assets		212,385		258,754			-
Liabilities
Convertible note payable		-		-			300,000
Advances from shareholders		-		307,141			-
Notes payable		-		-			200,000
Lease liability		-		260,919			-
Total liabilities		-		(568,060	)		(500,000	)
	$	212,385	$	(309,306	)	$	(500,000	)

	Fair Value Measurements at December 31, 2018
	Level 1		Level 2			Level 3
Assets
Cash	$	125,846	$	-		$	-
Total assets		125,846		-			-
Liabilities
Convertible note payable		-		-			300,000
Advances from shareholders		-		514,141			-
Notes payable		-		-			200,000
Total liabilities		-		(514,141	)		(500,000	)
	$	125,846	$	(514,141	)	$	(500,000	)

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2019 or the year ended December 31, 2018.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 6 – Other Current Assets

Other current assets included the following as of June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018
Security deposit	$	4,518	$	4,494
Prepaid expenses		67,350		30,850
Other receivables		64,911		-
Total	$	136,779	$	35,344

Note 7 – Fixed Assets

Fixed assets consist of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019			December 31, 2018
Land	$	179,731		$	-
Office equipment		23,469			18,314
Furniture and fixtures		32,216			23,595
Software		17,654			-
Equipment and machinery		310,919			-
Construction in progress		156,909			316,491
		720,898			358,400
Less: accumulated depreciation		(6,966	)		(1,961	)
Total	$	713,932		$	356,439

Construction in progress consists of equipment and capital improvements on the Popayán farm that have not yet been placed in service.

Depreciation and amortization expense totaled $5,005 and $103 for the six months ended June 30, 2019 and June 30, 2018, respectively.

Note 8 – Accrued Expenses

Accrued expenses consisted of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018
Accrued payroll	$	53,681	$	6,327
Accrued withholding taxes		6,232		6,387
Accrued ICA fees and contributions		11,936		8,514
Accrued interest		27,258		12,924
Deferred rent obligations		-		273
	$	99,107	$	34,425

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 9 – Convertible Note Payable

Convertible note payable consists of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On November 30, 2018, the Company received proceeds of $300,000 on a secured convertible note that carries a 6% interest rate from CSW Ventures, LP (“CSW”). The proceeds were used to fund the Company’s purchase of 875,000 shares of common stock, on a 1:4 split adjusted basis, of One World Pharma, Inc. The Note is due on demand. In the event that the Company consummates the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest may, at the option of the holder, be converted into such equity securities at a conversion price equal to eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing. The Company’s obligations under this Note are secured by a lien on the assets of the Company.	$	300,000	$	300,000

On January 14, 2019, the Company received proceeds of $500,000 on an unsecured convertible promissory note that carries a 6% interest rate from The Sanguine Group LLC. The Note was due January 14, 2022. In the event that the Company consummated the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest would automatically be converted into such equity securities at a conversion price equal to the lesser of (i) eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing, or (ii) $0.424 per share. The Company’s obligations under this Note were secured by a lien on the assets of the Company. A Qualified Financing subsequently occurred on February 4, 2019, at which time the principal and interest were converted into 1,253,493 shares of the Company’s common stock.		-		-
Less: unamortized debt discounts		-		-
Convertible note payable	$	300,000	$	300,000

In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt.

The aforementioned accounting treatment resulted in a total debt discount equal to $125,000 and $75,000 for the six months ended June 30, 2019 and the year ended December 31, 2018, respectively. The Company recorded finance expense in the amount of $125,000 for the six months ended June 30, 2019.

The convertible note limits the maximum number of shares that can be owned by the note holder as a result of the conversions to common stock to 4.99% of the Company’s issued and outstanding shares.

The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $10,323 and $125,000 of interest expense related to the debt discount for the six months ended June 30, 2019.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 10 – Advances from Shareholders

Advances from shareholders consist of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On various dates between May 3, 2018 and November 23, 2018, our CEO advanced short-term unsecured demand loans, bearing interest at 6% per annum, of an aggregate $514,141 to the Company, as follows: $10,000 – May 3, 2018 $100,000 – May 3, 2018 $82,000 – May 14, 2018 $15,000 – May 29, 2018 $57,141 – October 25, 2018 $100,000 – October 30, 2018 $50,000 – November 9, 2018 $50,000 – November 21, 2018 $50,000 – November 23, 2018 A total of $207,000 was repaid over various dates from March of 2019 through May of 2019, and $307,141 was exchanged for the note described below.	$	-	$	514,141

On February 13, 2019, a total of $307,141 of the advances from our CEO received from October 25, 2018 to November 23, 2018, as shown above, were exchanged for an amended and restated promissory note in the principal amount of $307,141 (the “Amended Note”). The Amended Note bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.		307,141		-

Total advances from shareholders	$	307,141	$	514,141

The Company recorded interest expense in the amount of $12,457 for the six months ended June 30, 2019.

Note 11 – Notes Payable

Notes payable consists of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On December 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.	$	100,000	$	100,000

On November 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.		100,000		100,000

Total notes payable	$	200,000	$	200,000

The Company recorded interest expense in the amount of $5,951 for the six months ended June 30, 2019.

The Company recognized interest expense for the six months ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018, respectively, as follows:

	June 30, 2019		June 30, 2018

Interest on convertible notes	$	10,323	$	-
Interest on advances from shareholders		12,457		1,761
Interest on notes payable		5,951		-
Amortization of beneficial conversion features		125,000		-
Interest on accounts payable		1,965		40
Total interest expense	$	155,696	$	1,801

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 12 – Leases

The Company’s corporate offices are within leased facilities. The Company doesn’t have any other office or equipment leases subject to the recently adopted ASU 2016-02. This real property lease contains a one-time renewal option for an additional 36 months. In the locations in which it is economically feasible to continue to operate, management expects that lease options will be exercised. The office lease contains provisions requiring payment of property taxes, utilities, insurance, maintenance and other occupancy costs applicable to the leased premise. As the Company’s lease does not provide an implicit discount rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.

The components of lease expense were as follows:

	For the Six Months Ended
	June 30, 2019
Finance lease cost:
Amortization of assets	$	19,971
Interest on lease liabilities		9,158
Total lease cost	$	29,129

Supplemental balance sheet information related to leases were as follows:

	June 30, 2019
Finance lease:
Right-of-use asset	$	278,725
Accumulated amortization		(19,971	)
Right-of-use asset, net	$	258,754

Current portion of finance lease liability	$	38,561
Long-term finance lease liability		222,358
Total finance lease liability	$	260,919

Weighted average remaining lease term:
Operating leases		N/A
Finance leases		5.5 years

Weighted average discount rate:
Operating leases		N/A
Finance leases		6.75	%

Supplemental cash flow and other information related to leases was as follows:

	For the Six Months Ended
	June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used for finance leases	$	26,964

Leased assets obtained in exchange for lease liabilities:
Total operating lease liabilities	$	-
Total finance lease liabilities	$	260,919

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

The Company’s maturities of lease liabilities under finance leases as of June 30, 2019 are as follows:

	Finance
	Leases

2019	$	27,234
2020		55,824
2021		57,498
2022		59,223
2023		61,000
Thereafter		51,957
Total		312,876
Less interest		56,461
Present value of lease liabilities		260,919
Less current portion		38,561
Long-term lease liabilities	$	222,358

There were no operating leases as of June 30, 2019.

Note 13 – Changes in Stockholders’ Equity

One World Pharma is authorized to issue an aggregate of 75,000,000 shares of common stock with a par value of $0.001. As of June 30, 2019, there were 39,922,899 shares of common stock issued and outstanding. The par value of OWP Ventures’ common stock was $0.0001 per share. The par value presented for OWP Ventures’ transactions have been retroactively adjusted to reflect the par value of One World Pharma in this Quarterly Report on Form 10-Q.

Reverse Stock Split

On January 10, 2019, One World Pharma, Inc. effected a 1-for-4 reverse stock split. No fractional shares were issued, and no cash or other consideration was paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. One World Pharma, Inc. was authorized to issue 75,000,000 shares of common stock prior to the Reverse Stock Split, which remains unaffected. The Reverse Stock Split did not have any effect on the stated par value of the common stock. Unless otherwise stated, all share and per share information in this Quarterly Report on Form 10-Q has been retroactively adjusted to reflect the Reverse Stock Split.

Cash Received on Subscriptions Receivable

On various dates between January 30, 2019 and February 5, 2019, the Company received $602 from two of the Company’s founders for sales of common stock of OWP Ventures during 2018 at $0.001 per share on subscriptions receivable.

Common Stock Sales

On various dates between January 3, 2019 and February 19, 2019, the Company sold an aggregate 3,900,000 shares of common stock of OWP Ventures at $0.50 per share for total proceeds of $1,950,000.

Common Stock Issued for Debt Conversion

On February 4, 2019, a total of 1,253,493 shares of common stock of OWP Ventures were issued pursuant to the conversion of $501,397 of convertible debt owed to The Sanguine Group LLC, consisting of $500,000 of principal and $1,397 of interest.

Common Stock Issued for Services

On February 18, 2019, the Company issued 30,000 shares of common stock of OWP Ventures to a consultant for services. The total fair value of the common stock was $15,000 based recent independent third-party sales at $0.50 per share.

ONE WORLD PHARMA, INC.

(Formerly Punto Group, Corp.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Common Stock Options Issued for Services

On February 8, 2019, the Company awarded cashless options to a service provider to acquire up to 100,000 shares of common stock, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 8,333 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 8,337 shares on the one-year anniversary of the effective date.

On February 8, 2019, the Company awarded cashless options to one of our directors to acquire up to 125,000 shares of common stock, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 10,416 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 10,424 shares on the one-year anniversary of the effective date.

On January 28, 2019, the Company awarded cashless options to a service provider to acquire up to 500,000 shares of common stock, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 41,666 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 41,674 shares on the one-year anniversary of the effective date.

On January 28, 2019, the Company awarded cashless options to a service provider to acquire up to 100,000 shares of common stock, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 8,333 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 8,337 shares on the one-year anniversary of the effective date.

On October 24, 2018, the Company issued 50,000 shares of common stock to a consultant in settlement for services. The total fair value of the common stock was $21,000 based recent independent third-party sales at $0.42 per share.

A total of $560,958 was expensed during the six months ending June 30, 2019 pursuant to the options issued for services.

Common Stock Issued for Share Exchange

On February 21, 2019, One World Pharma acquired OWP Ventures in the Merger. As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) the options described above to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; and (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled.

Note 14 – Income Taxes

The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.

For the six months ended June 30, 2019 and the year ended December 31, 2018, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2019, the Company had approximately $3,681,600 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2038.

Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2019 and December 31, 2018, respectively.

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Note 15 – Subsequent Events

Common Stock Sales

On August 12, 2019, the Company sold 1,059,000 shares of common stock at $0.50 per share for proceeds of $529,500.

On July 29, 2019, the Company sold 200,000 shares of common stock at $0.50 per share for proceeds of $100,000.

On July 17, 2019, the Company sold 285,000 shares of common stock at $0.50 per share for proceeds of $142,500.

Debt Exchange

On July 22, 2019, the Company exchanged two outstanding demand notes bearing 6% interest (See Note 11), in the aggregate amount of $207,332, consisting of $200,000 of principal and $7,332 of accrued interest, for a convertible promissory note in the principal amount of $207,332, bearing 6% interest, due on demand and convertible into common stock at a fixed conversion price of $0.50 per share.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The information contained in this Form 10-Q is intended to update the information contained in our Annual Report on Form 10-K for the year ended December 31, 2018 and Current Report on Form 8-K with respect to the Merger originally filed with the SEC on February 25, 2019, as amended and restated on July 12, 2019 (the “Super 8-K”), and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K and Super 8-K. The following discussion and analysis also should be read together with our financial statements and the notes to the financial statements included elsewhere in this Form 10-Q.

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in the Super 8-K in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this quarterly report on Form 10-Q. The following should also be read in conjunction with the unaudited Financial Statements and notes thereto that appear elsewhere in this report.

Overview

On February 21, 2019, One World Pharma, Inc. (“Company,” “we” or “our”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with OWP Merger Subsidiary, Inc. (“OWP Merger Sub), our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”). Under the Merger Agreement, the acquisition of OWP Ventures by the Company was effected by the merger of OWP Merger Sub with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary (the “Merger”). The closing (the “Closing”) of the Merger occurred on February 21, 2019. As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our Common Stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our Common Stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our Common Stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our Common Stock in a future “Qualified Offering”; (d) 875,000 shares of our Common Stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors.

OWP Ventures, Inc. is a holding company formed in Delaware on March 27, 2018 to enter and support the cannabis industry, and on May 30, 2018, it acquired One World Pharma S.A.S (“OWP SAS”). One World Pharma S.A.S, is a licensed cannabis cultivation, production and distribution (export) company located in Popayán, Colombia (nearest major city is Cali). We plan to be a producer of raw cannabis and hemp plant ingredients for both medical and industrial uses across the globe. We have received licenses to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes. Specifically, we are one of the only companies in Colombia to receive seed, cultivation, extraction and export licenses from the Colombian government. Currently, we own approximately 30 acres and have a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we have entered into agreements with local farming co-operatives that include small farmers and indigenous tribe members, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We planted our first crop of cannabis in 2018, which we began harvesting in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced. To date, we have not yet generated any revenues from our activities.

The Merger was accounted for as a reverse merger (recapitalization) with OWP Ventures deemed to be the accounting acquirer. Accordingly, the financial statements included in this Quarterly Report on Form 10-Q and the following discussion reflect the historical operations of OWP Ventures and its wholly-owned subsidiary OWP SAS prior to the Merger, and that of the combined company following the Merger. The historical financial information for One World Pharma, Inc. (formerly Punto Group Corp.) prior to the Merger has been omitted.

Results of Operations for the Three Months Ended June 30, 2019 and 2018:

We have not generated any revenues to date, and there were limited expenses in the comparative period prior to the acquisition of One World Pharma, SAS by OWP Ventures, Inc. on May 30, 2018, when activities were ramped up to develop operations.

The following table summarizes selected items from the statement of operations for the three months ended June 30, 2019 and 2018.

	Three Months Ended June 30,						Increase /
	2019			2018			(Decrease)
Revenues	$	-		$	-		$	-

Operating expenses:
General and administrative		565,167			124,840			440,327
Professional fees		741,542			156,977			584,565
Total operating expenses:		1,306,709			281,817			1,024,892

Operating loss		(1,306,709	)		(281,817	)		(1,024,892	)

Total other expense		(18,519	)		(1,801	)		(16,718	)

Net loss	$	(1,325,228	)	$	(283,618	)	$	(1,041,610	)

Revenues

We have not generated any revenues to date.

General and Administrative Expenses

General and administrative expenses for the three months ended June 30, 2019 were $565,167, compared to $124,840 during the three months ended June 30, 2018, an increase of $440,327, or 353%. The expenses for the current period consisted primarily of compensation expenses, office rent, and travel costs.

Professional Fees

Professional fees for the three months ended June 30, 2019 were $741,542, compared to $156,977 during the three months ended June 30, 2018, an increase of $584,565, or 372%. Professional fees included non-cash, stock-based compensation of $395,715 during the three months ended June 30, 2019. Professional fees increased primarily due to increased stock-based compensation during the current period.

Other Income (Expense)

Other expenses, on a net basis, for the three months ended June 30, 2019 were $18,519, compared to $1,801 during the three months ended June 30, 2018, an increase of $16,718, or 928%. Other expenses consisted of a loss on disposal of assets of $4,087 and $14,579 of interest expense, as offset by $147 of interest income for the three months ended June 30, 2019. Other expenses during the three months ended June 30, 2018 consisted of $1,801 of interest expense.

Net Loss

Net loss for the three months ended June 30, 2019 was $1,325,228, or $0.03 per share, compared to $283,618, or $0.01 per share, during the three months ended June 30, 2018, an increase of $1,041,610, or 367%. The net loss for the three months ended June 30, 2019 included non-cash expenses consisting of $2,436 of depreciation, $395,715 of stock-based compensation and $14,579 of accrued interest.

Results of Operations for the Six Months Ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018:

The following table summarizes selected items from the statement of operations for the six months ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018.

	For the Six Months Ended			From Inception (March 27, 2018)			Increase /
	June 30, 2019			to June 30, 2018			(Decrease)
Revenues	$	-		$	-		$	-

Operating expenses:
General and administrative		1,044,787			124,840			919,947
Professional fees		1,444,422			156,977			1,287,445
Total operating expenses:		2,489,209			281,817			2,207,392

Operating loss		(2,489,209	)		(281,817	)		(2,207,392	)

Total other expense		(159,535	)		(1,801	)		(157,734	)

Net loss	$	(2,648,744	)	$	(283,618	)	$	(2,365,126	)

Revenues

We have not generated any revenues to date.

General and Administrative Expenses

General and administrative expenses for the six months ended June 30, 2019 were $1,044,787, compared to $124,840 during the period from inception (March 27, 2018) to June 30, 2018, an increase of $919,947, or 737%. The expenses for the current period consisted primarily of compensation expenses, office rent, and travel costs.

Professional Fees

Professional fees for the six months ended June 30, 2019 were $1,444,422, compared to $156,977 during the six months ended June 30, 2018, an increase of $1,287,445, or 820%. Professional fees included non-cash, stock-based compensation of $664,255 during the period from inception (March 27, 2018) to June 30, 2018. Professional fees increased primarily due to increased stock-based compensation during the current period.

Other Income (Expense)

Other expenses, on a net basis, for the six months ended June 30, 2019 were $159,535, compared to $1,801 during the six months ended June 30, 2018, an increase of $157,734, or 8,758%. Other expenses consisted of a loss on disposal of assets of $4,087 and $155,696 of interest expense, as offset by $248 of interest income for the six months ended June 30, 2019. Other expenses during the period from inception (March 27, 2018) to June 30, 2018 consisted of $1,801 of interest expense.

Net Loss

Net loss for the six months ended June 30, 2019 was $2,648,744, or $0.07 per share, compared to $283,618, or $0.01 per share, during the period from inception (March 27, 2018) to June 30, 2018, an increase of $2,365,126, or 834%. The net loss for the six months ended June 30, 2019 included non-cash expenses consisting of $5,005 of depreciation, $664,255 of stock-based compensation and $155,696 of accrued interest, including $125,000 of amortization on debt discounts.

Liquidity and Capital Resources

The following is a summary of the Company’s cash flows provided by (used in) operating, investing, financing activities and effect of exchange rate changes on cash for the six month period ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018:

	2019			2018
Operating Activities	$	(1,933,479	)	$	(285,897	)
Investing Activities		(366,585	)		(11,585	)
Financing Activities		2,243,602			707,000
Effect of exchange rate changes on cash		143,001			35,402
Net Increase in Cash	$	86,539		$	444,920

Net Cash Used in Operating Activities

During the six months ended June 30, 2019, net cash used in operating activities was $1,933,479, compared to net cash used in operating activities of $285,897 for the period from inception (March 27, 2018) to June 30, 2018. The cash used in operating activities was primarily attributable to our net loss.

Net Cash Used in Investing Activities

During the six months ended June 30, 2019, net cash used in investing activities was $366,585, compared to net cash used in investing activities of $11,585 for the period from inception (March 27, 2018) to June 30, 2018. The cash used in investing activities consisted of purchases of fixed assets.

Net Cash Provided by Financing Activities

During the six months ended June 30, 2019, net cash provided by financing activities was $2,243,602, compared to net cash used in financing activities of $707,000 for the period from inception (March 27, 2018) to June 30, 2018. The current period consisted of $500,000 of convertible debt financing that was subsequently converted into 1,253,493 shares of common stock at $0.40 per share, repayments of $207,000 to shareholders on previous advances, proceeds of $602 on subscriptions receivable and $1,950,000 of proceeds received from the sale of stock at $0.50 per share.

Ability to Continue as a Going Concern

As of June 30, 2019, our balance of cash on hand was $212,385, and we had a working capital deficit of $745,796 and an accumulated deficit of $4,608,726. We currently may not have sufficient funds to sustain our operations for the next twelve months and we may need to raise additional cash to fund our operations to the extent necessary to provide working capital.

The Company has incurred recurring losses from operations resulting in an accumulated deficit, and, as set forth above, the Company’s cash on hand is not sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing its cannabis cultivation activities and expects to begin revenue generating export operations in the first quarter of 2020. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. In the event revenues do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that we will be successful in achieving these objectives, becoming profitable or continuing our business without either a temporary interruption or a permanent cessation. Additional financing may result in substantial dilution to existing stockholders.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have no outstanding off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts. We do not engage in trading activities involving non-exchange traded contracts.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the presentation of our financial condition and results of operations and require management’s subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments.

While our significant accounting policies are more fully described in notes to our consolidated financial statements appearing elsewhere in this Form 10-Q, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we used in the preparation of our financial statements.

Revenue Recognition

There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the six months ended June 30, 2019, or the year ended December 31, 2018.

Stock-Based Compensation

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, who are one and the same, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2019, including our inability to timely file this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer, who are one and the same, concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) or in other factors that occurred during the period of our evaluation or subsequent to the date we carried out our evaluation which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. The design of any system of controls and procedures is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any system of controls and procedures will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not a party to any legal or administrative proceedings that we believe, individually or in the aggregate, would be likely to have a material adverse effect on our financial condition or results of operations.

ITEM 1A.

RISK FACTORS

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide the information required by this Item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no issuances of equity securities by the Company that were exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 4(a)(2) of the Securities Act of 1933 during the six month period ended June 30, 2019.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

Exhibits

Exhibit		Description
2.1		Agreement and Plan of Merger dated February 21, 2019, among the Registrant, OWP Merger Subsidiary Inc. and OWP Ventures, Inc. (incorporated by reference to Exhibit 2.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019)
3.1		Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 24, 2014)
3.2		Certificate of Amendment to Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 8, 2019)
3.3		Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 24, 2014)
21.1		Subsidiaries (incorporated by reference to Exhibit 21.1 of the Form 8-K filed with the Securities and Exchange Commission by One World Pharma, Inc. on February 25, 2019)
31.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)
32.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.SCH*		XBRL Schema Document
101.CAL*		XBRL Calculation Linkbase Document
101.DEF*		XBRL Definition Linkbase Document
101.LAB*		XBRL Labels Linkbase Document
101.PRE*		XBRL Presentation Linkbase Document

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 13, 2019

	One World Pharma, Inc.

	/s/ Craig Ellins
	Craig Ellins
	Chief Executive Officer
	(Principal Executive Officer and Principal Financial Officer)

GRAPHIC 2 form10-q_001.jpg begin 644 form10-q_001.jpg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ex31-1.htm

EXHIBIT 31.1

CERTIFICATIONS PURSUANT TO
RULE 13A-14(A) OR RULE 15D-14(A),
AS ADOPTED PURSUANT TO
RULE 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Craig Ellins, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of One World Pharma, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ Craig Ellins
	Craig Ellins
	Chief Executive Officer and Chief Financial Officer

Dated: August 13, 2019

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of One World Pharma, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2019 (the “Report”) I, Craig Ellins, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2019

/s/ Craig Ellins
Name:	Craig Ellins
Title:	Chief Executive Officer and Principal Financial Officer

EX-101.INS 5 owpc-20190630.xml XBRL INSTANCE FILE 0001622244 2019-01-01 2019-06-30 0001622244 2019-06-30 0001622244 2018-12-31 0001622244 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001622244 us-gaap:CommonStockMember 2018-12-31 0001622244 us-gaap:CommonStockMember 2019-06-30 0001622244 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001622244 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001622244 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001622244 us-gaap:RetainedEarningsMember 2018-12-31 0001622244 us-gaap:RetainedEarningsMember 2019-06-30 0001622244 2018-06-30 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-02-20 2019-02-21 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-02-21 0001622244 2019-01-09 2019-01-10 0001622244 2019-01-10 0001622244 2018-03-27 2018-06-30 0001622244 OWPC:SubscriptionsReceivableMember 2019-01-01 2019-06-30 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001622244 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-06-30 0001622244 OWPC:SubscriptionsReceivableMember 2018-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001622244 us-gaap:NoncontrollingInterestMember 2018-12-31 0001622244 OWPC:SubscriptionsReceivableMember 2019-06-30 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001622244 us-gaap:NoncontrollingInterestMember 2019-06-30 0001622244 us-gaap:CommonStockMember 2018-03-27 2018-12-31 0001622244 us-gaap:CommonStockMember 2018-03-26 0001622244 us-gaap:AdditionalPaidInCapitalMember 2018-03-27 2018-12-31 0001622244 us-gaap:AdditionalPaidInCapitalMember 2018-03-26 0001622244 OWPC:SubscriptionsReceivableMember 2018-03-27 2018-12-31 0001622244 OWPC:SubscriptionsReceivableMember 2018-03-26 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-27 2018-12-31 0001622244 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-26 0001622244 us-gaap:RetainedEarningsMember 2018-03-27 2018-12-31 0001622244 us-gaap:RetainedEarningsMember 2018-03-26 0001622244 us-gaap:NoncontrollingInterestMember 2018-03-27 2018-12-31 0001622244 us-gaap:NoncontrollingInterestMember 2018-03-26 0001622244 2018-03-27 2018-12-31 0001622244 2018-03-26 0001622244 OWPC:MergerAgreementMember OWPC:OWPVenturesIncMember 2019-01-01 2019-06-30 0001622244 OWPC:CEOMember 2018-10-25 0001622244 OWPC:CEOMember 2018-11-23 0001622244 OWPC:PromissoryNotesMember 2019-02-13 0001622244 us-gaap:FairValueInputsLevel1Member 2019-06-30 0001622244 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001622244 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001622244 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001622244 us-gaap:FairValueInputsLevel3Member 2019-06-30 0001622244 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001622244 us-gaap:OfficeEquipmentMember 2019-06-30 0001622244 us-gaap:OfficeEquipmentMember 2018-12-31 0001622244 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001622244 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001622244 us-gaap:SoftwareDevelopmentMember 2019-06-30 0001622244 us-gaap:SoftwareDevelopmentMember 2018-12-31 0001622244 us-gaap:ConstructionInProgressMember 2019-06-30 0001622244 us-gaap:ConstructionInProgressMember 2018-12-31 0001622244 OWPC:ConvertibleNotePayableOneMember 2019-06-30 0001622244 OWPC:ConvertibleNotePayableOneMember 2018-12-31 0001622244 OWPC:ConvertibleNotePayableTwoMember 2019-06-30 0001622244 OWPC:ConvertibleNotePayableTwoMember 2018-12-31 0001622244 OWPC:ConvertibleNotePayableOneMember OWPC:CSWVenturesLPMember 2018-11-30 0001622244 OWPC:ConvertibleNotePayableOneMember OWPC:CSWVenturesLPMember 2018-11-29 2018-11-30 0001622244 OWPC:ConvertibleNotePayableOneMember 2018-11-29 2018-11-30 0001622244 OWPC:ConvertibleNotePayableTwoMember 2019-01-13 2019-01-14 0001622244 OWPC:ConvertibleNotePayableTwoMember 2019-01-14 0001622244 OWPC:ShortTermUnsecuredDemandLoansOneMember 2019-06-30 0001622244 OWPC:ShortTermUnsecuredDemandLoansOneMember 2018-12-31 0001622244 OWPC:ShortTermUnsecuredDemandLoansTwoMember 2019-06-30 0001622244 OWPC:ShortTermUnsecuredDemandLoansTwoMember 2018-12-31 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2019-06-30 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-05-03 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-05-14 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-05-29 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-10-25 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-10-30 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-11-09 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-11-21 0001622244 OWPC:ShortTermUnsecuredDemandLoansMember 2018-11-23 0001622244 OWPC:ShortTermUnsecuredDemandLoansOneMember 2018-05-03 0001622244 OWPC:NotesPayableMember 2019-01-01 2019-06-30 0001622244 OWPC:NotesPayableOneMember 2019-06-30 0001622244 OWPC:NotesPayableOneMember 2018-12-31 0001622244 OWPC:NotesPayableTwoMember 2019-06-30 0001622244 OWPC:NotesPayableTwoMember 2018-12-31 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:CSWVenturesLPMember 2018-12-26 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:CSWVenturesLPMember 2018-12-25 2018-12-26 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:CSWVenturesLPMember 2018-11-26 0001622244 OWPC:UnsecuredPromissoryNoteMember OWPC:CSWVenturesLPMember 2018-11-25 2018-11-26 0001622244 OWPC:OneWorldPharmaIncMember 2019-01-01 2019-06-30 0001622244 OWPC:OWPVenturesIncMember 2019-01-01 2019-06-30 0001622244 OWPC:OneWorldPharmaSASMember 2019-01-01 2019-06-30 0001622244 OWPC:OWPVenturesIncMember 2019-01-30 2019-02-05 0001622244 OWPC:OWPVenturesIncMember 2019-02-05 0001622244 OWPC:OWPVenturesIncMember 2019-01-03 2019-02-19 0001622244 OWPC:OWPVenturesIncMember 2019-02-19 0001622244 OWPC:ServiceProviderMember OWPC:OWPVenturesIncMember 2019-02-07 2019-02-08 0001622244 OWPC:ServiceProviderMember OWPC:OWPVenturesIncMember 2019-01-27 2019-01-28 0001622244 OWPC:ServiceProviderMember OWPC:OWPVenturesIncMember OWPC:OneYearAnniversaryMember 2019-02-07 2019-02-08 0001622244 OWPC:ServiceProviderMember OWPC:OWPVenturesIncMember OWPC:OneYearAnniversaryMember 2019-01-27 2019-01-28 0001622244 srt:DirectorMember OWPC:OWPVenturesIncMember 2019-02-07 2019-02-08 0001622244 srt:DirectorMember OWPC:OWPVenturesIncMember OWPC:OneYearAnniversaryMember 2019-02-07 2019-02-08 0001622244 OWPC:ServiceProviderOneMember OWPC:OWPVenturesIncMember 2019-01-27 2019-01-28 0001622244 OWPC:ServiceProviderOneMember OWPC:OWPVenturesIncMember OWPC:OneYearAnniversaryMember 2019-01-27 2019-01-28 0001622244 OWPC:ConsultantMember 2018-10-23 2018-10-24 0001622244 OWPC:ConsultantMember 2018-10-24 0001622244 OWPC:MergerAgreementMember 2019-02-20 2019-02-21 0001622244 OWPC:MergerAgreementMember 2019-02-21 0001622244 OWPC:OWPVenturesIncMember 2019-06-30 0001622244 OWPC:SanguineGroupLLCMember 2019-02-03 2019-02-04 0001622244 OWPC:SanguineGroupLLCMember 2019-02-04 0001622244 OWPC:OWPVenturesIncMember 2019-02-17 2019-02-18 0001622244 OWPC:OWPVenturesIncMember 2019-02-18 0001622244 2019-08-12 0001622244 2019-04-01 2019-06-30 0001622244 2018-04-01 2018-06-30 0001622244 2019-03-01 2019-05-31 0001622244 OWPC:PromissoryNotesMember 2019-02-12 2019-02-13 0001622244 us-gaap:MachineryAndEquipmentMember 2019-06-30 0001622244 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001622244 us-gaap:LandMember 2019-06-30 0001622244 us-gaap:LandMember 2018-12-31 0001622244 us-gaap:SubsequentEventMember 2019-07-28 2019-07-29 0001622244 us-gaap:SubsequentEventMember 2019-07-29 0001622244 us-gaap:SubsequentEventMember 2019-07-16 2019-07-17 0001622244 us-gaap:SubsequentEventMember 2019-07-17 0001622244 us-gaap:SubsequentEventMember OWPC:ConvertiblePromissoryNotesMember 2019-07-22 0001622244 us-gaap:SubsequentEventMember OWPC:TwoOutstandingDemandNotesMember 2019-07-22 0001622244 us-gaap:SubsequentEventMember 2019-08-11 2019-08-12 0001622244 us-gaap:SubsequentEventMember 2019-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure OWPC:Number One World Pharma, Inc. One World Pharma, Inc OWP Ventures, Inc. One World Pharma S.A.S. 0001622244 10-Q 2019-06-30 false --12-31 true Non-accelerated Filer true Q2 2019 41466899 false

212385

125846

374142

161190

175129

121194

99107

34425

307141

514141

307141

514141

307141

514141

10000

82000

15000

57141

100000

50000

100000

1119938

1169760

1342296

1169760

39923

34292

-4608726

-1959982

1416370

517629

0.001

0.0001

75000000

39922899

34291905

39922899

34291905

-0.06

-0.01

-0.03

-0.01

38779975

29410501

39922899

29777996

-2648744

-283618

-1959982

-101

-1960083

-1325228

-283618

-2489209

-281817

-1306709

-281817

2489209

281817

1306709

281817

1444422

156977

741542

156977

1044787

124840

565167

124840

53935

7957

66079

2753

-1933479

-285897

2243602

707000

14965

1-for-4 reverse stock split

136779

35344

24978

258754

69542

38561

300000

200000

100000

222358

4503966

1278352

138911

-4090

-101

6012500

143001

35402

143001

-4090

151288

602

23411905

875000

680000

50000

30000

680

284920

285600

21000

15000

602 602 602

-875000

875000

501397

9306

1950000

500000

602

500000

300000

500000

-366585

-11585

366585

11585

260919 649255

15000

125000

75000

207000

Note 3 – Reverse Merger   On February 21, 2019, One World Pharma, Inc. entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, which is the parent company of OWP Colombia. Pursuant to the Merger Agreement, we acquired OWP Ventures (and indirectly, OWP Colombia) by the merger of OWP Merger Subsidiary with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary. As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors.

Note 6 – Other Current Assets   Other current assets included the following as of June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif">Security deposit</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">4,518</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">4,494</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Prepaid expenses</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">67,350</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">30,850</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Other receivables</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">64,911</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">136,779</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">35,344</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Note 7 – Fixed Assets   Fixed assets consist of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; font-family: Times New Roman, Times, Serif">Land</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">179,731</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Office equipment</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">23,469</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">18,314</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Furniture and fixtures</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">32,216</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">23,595</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif">Software</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">17,654</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Equipment and machinery</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">310,919 </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Construction in progress</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">156,909</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">316,491</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">720,898</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">358,400</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(6,966</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(1,961</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">713,932</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">356,439</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   Construction in progress consists of equipment and capital improvements on the Popayán farm that have not yet been placed in service.   Depreciation and amortization expense totaled $5,005 and $103 for the six months ended June 30, 2019 and June 30, 2018, respectively.

Note 8 – Accrued Expenses   Accrued expenses consisted of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font-family: Times New Roman, Times, Serif">Accrued payroll</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">53,681</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">6,327</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Accrued withholding taxes</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6,232</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6,387</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Accrued ICA fees and contributions</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">11,936</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">8,514</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Accrued interest</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">27,258</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">12,924</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Deferred rent obligations</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">273</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">99,107</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">34,425</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Note 9 – Convertible Note Payable   Convertible note payable consists of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif">On November 30, 2018, the Company received proceeds of $300,000 on a secured convertible note that carries a 6% interest rate from CSW Ventures, LP (“CSW”). The proceeds were used to fund the Company’s purchase of 875,000 shares of common stock, on a 1:4 split adjusted basis, of One World Pharma, Inc. The Note is due on demand. In the event that the Company consummates the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest may, at the option of the holder, be converted into such equity securities at a conversion price equal to eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing. The Company’s obligations under this Note are secured by a lien on the assets of the Company.</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">On January 14, 2019, the Company received proceeds of $500,000 on an unsecured convertible promissory note that carries a 6% interest rate from The Sanguine Group LLC. The Note was due January 14, 2022. In the event that the Company consummated the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest would automatically be converted into such equity securities at a conversion price equal to the lesser of (i) eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing, or (ii) $0.424 per share. The Company’s obligations under this Note were secured by a lien on the assets of the Company. A Qualified Financing subsequently occurred on February 4, 2019, at which time the principal and interest were converted into 1,253,493 shares of the Company’s common stock.</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less: unamortized debt discounts</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Convertible note payable</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt.   The aforementioned accounting treatment resulted in a total debt discount equal to $125,000 and $75,000 for the six months ended June 30, 2019 and the year ended December 31, 2018, respectively. The Company recorded finance expense in the amount of $125,000 for the six months ended June 30, 2019.   The convertible note limits the maximum number of shares that can be owned by the note holder as a result of the conversions to common stock to 4.99% of the Company’s issued and outstanding shares.   The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $10,323 and $125,000 of interest expense related to the debt discount for the six months ended June 30, 2019.

Note 10 – Advances from Shareholders   Advances from shareholders consist of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font-family: Times New Roman, Times, Serif">On various dates between May 3, 2018 and November 23, 2018, our CEO advanced short-term unsecured demand loans, bearing interest at 6% per annum, of an aggregate $514,141 to the Company, as follows:     $ 10,000 – May 3, 2018     $100,000 – May 3, 2018     $ 82,000 – May 14, 2018     $ 15,000 – May 29, 2018     $ 57,141 – October 25, 2018     $100,000 – October 30, 2018     $ 50,000 – November 9, 2018     $ 50,000 – November 21, 2018     $ 50,000 – November 23, 2018 A total of $207,000 was repaid over various dates from March of 2019 through May of 2019, and $307,141 was exchanged for the note described below. </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">514,141</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">On February 13, 2019, a total of $307,141 of the advances from our CEO received from October 25, 2018 to November 23, 2018, as shown above, were exchanged for an amended and restated promissory note in the principal amount of $307,141 (the “Amended Note”). The Amended Note bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">307,141</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Total advances from shareholders</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">307,141</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">514,141</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   The Company recorded interest expense in the amount of $12,457 for the six months ended June 30, 2019. Note 11 – Notes Payable   Notes payable consists of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font-family: Times New Roman, Times, Serif">On December 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">100,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">100,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">On November 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">100,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">100,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Total notes payable</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   The Company recorded interest expense in the amount of $5,951 for the six months ended June 30, 2019.   The Company recognized interest expense for the six months ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018, respectively, as follows:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2018</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(205,255,205); font: 10pt Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Interest on convertible notes</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif">10,323</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Interest on advances from shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">12,457</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,761</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(205,255,205); font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Interest on notes payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5,951</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">-</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Amortization of beneficial conversion features</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">125,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">-</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(205,255,205); font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Interest on accounts payable</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,965</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Total interest expense</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">155,696</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,801</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

Note 12 – Leases   The Company’s corporate offices are within leased facilities. The Company doesn’t have any other office or equipment leases subject to the recently adopted ASU 2016-02. This real property lease contains a one-time renewal option for an additional 36 months. In the locations in which it is economically feasible to continue to operate, management expects that lease options will be exercised. The office lease contains provisions requiring payment of property taxes, utilities, insurance, maintenance and other occupancy costs applicable to the leased premise. As the Company’s lease does not provide an implicit discount rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.   The components of lease expense were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">For the Six Months Ended</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Finance lease cost:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 73%; text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Amortization of assets</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 23%; text-align: right; font-family: Times New Roman, Times, Serif">19,971</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Interest on lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">9,158</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Total lease cost</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">29,129</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   Supplemental balance sheet information related to leases were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Finance lease:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 73%; text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Right-of-use asset</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 23%; text-align: right; font-family: Times New Roman, Times, Serif">278,725</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Accumulated amortization</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(19,971</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Right-of-use asset, net</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">258,754</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Current portion of finance lease liability</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">38,561</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Long-term finance lease liability</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">222,358</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total finance lease liability</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Weighted average remaining lease term:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Operating leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">N/A</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Finance leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.5 years</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Weighted average discount rate:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Operating leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">N/A</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Finance leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6.75</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr> </table>   Supplemental cash flow and other information related to leases was as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">For the Six Months Ended</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 73%; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Operating cash flows used for finance leases</td><td style="width: 2%; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 23%; border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">26,964</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Leased assets obtained in exchange for lease liabilities:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total finance lease liabilities</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   The Company’s maturities of lease liabilities under finance leases as of June 30, 2019 are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">Finance</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Leases</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 78%; text-align: justify; font-family: Times New Roman, Times, Serif">2019</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman, Times, Serif">27,234</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">55,824</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2021</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">57,498</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">59,223</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2023</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">61,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Thereafter</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">51,957</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; text-indent: 8.25pt; font-family: Times New Roman, Times, Serif">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">312,876</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less interest</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">56,461</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; text-indent: 8.25pt; font-family: Times New Roman, Times, Serif">Present value of lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less current portion</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">38,561</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 8.25pt; font-family: Times New Roman, Times, Serif">Long-term lease liabilities</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">222,358</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   There were no operating leases as of June 30, 2019.

Cash in Excess of FDIC Insured Limits   The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. The Company didn’t have any amounts in excess of FDIC insured limits at June 30, 2019, and has not experienced any losses in such accounts.

Foreign Currency Translation   The functional currency of the Company is Columbian Peso (COP). The Company has maintained its financial statements using the functional currency, and translated those financial statements to the US Dollar (USD) throughout this report. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods.

Comprehensive Income   The Company has adopted ASC 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

Principles of Consolidation   The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif">State of</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Name of Entity</td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif">Incorporation</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif">Relationship</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">One World Pharma, Inc.(1)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Nevada</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Parent</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">OWP Ventures, Inc.(2)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Delaware</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Subsidiary</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">One World Pharma S.A.S.(3)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Colombia</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Subsidiary</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   (1)Holding company in the form of a corporation. (2)Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.  (3)Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogotá on July 18, 2017. Its headquarters are located in Bogotá.   The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. The Company's headquarters are located in Las Vegas, Nevada and substantially all of its production efforts are within Popayán, Colombia.

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif">State of</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Name of Entity</td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif">Incorporation</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif">Relationship</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">One World Pharma, Inc.(1)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Nevada</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Parent</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">OWP Ventures, Inc.(2)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Delaware</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Subsidiary</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">One World Pharma S.A.S.(3)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Colombia</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Subsidiary</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   (1)Holding company in the form of a corporation. (2)Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.  (3)Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogotá on July 18, 2017. Its headquarters are located in Bogotá.

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheet as of June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Fair Value Measurements at June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 1</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 2</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 3</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Assets</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 46%; font-family: Times New Roman, Times, Serif">Cash</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif">212,385</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Right-of-use asset</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">258,754</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total assets</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">212,385</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">258,754</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Convertible note payable</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Advances from shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">307,141</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Notes payable</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Lease liability</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total liabilities</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(568,060</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">212,385</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(309,306</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Fair Value Measurements at December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 1</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 2</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 3</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,255,204)"> <td style="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Assets</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 46%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Cash</td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">125,846</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total assets</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">125,846</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-weight: bold; padding-left: 20pt; text-align: center; font-family: Times New Roman, Times, Serif">Liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Convertible note payable</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Advances from shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">514,141</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Notes payable</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total liabilities</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(514,141</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">125,846</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(514,141</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr></table>

Other current assets included the following as of June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif">Security deposit</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">4,518</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">4,494</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Prepaid expenses</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">67,350</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">30,850</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Other receivables</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">64,911</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">136,779</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">35,344</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Fixed assets consist of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; font-family: Times New Roman, Times, Serif">Land</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">179,731</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Office equipment</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">23,469</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">18,314</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Furniture and fixtures</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">32,216</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">23,595</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif">Software</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">17,654</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Equipment and machinery</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">310,919 </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Construction in progress</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">156,909</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">316,491</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">720,898</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">358,400</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(6,966</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(1,961</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">713,932</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">356,439</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Accrued expenses consisted of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font-family: Times New Roman, Times, Serif">Accrued payroll</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">53,681</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">6,327</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Accrued withholding taxes</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6,232</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6,387</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Accrued ICA fees and contributions</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">11,936</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">8,514</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Accrued interest</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">27,258</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">12,924</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Deferred rent obligations</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">273</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">99,107</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">34,425</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>

Convertible note payable consists of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif">On November 30, 2018, the Company received proceeds of $300,000 on a secured convertible note that carries a 6% interest rate from CSW Ventures, LP (“CSW”). The proceeds were used to fund the Company’s purchase of 875,000 shares of common stock, on a 1:4 split adjusted basis, of One World Pharma, Inc. The Note is due on demand. In the event that the Company consummates the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest may, at the option of the holder, be converted into such equity securities at a conversion price equal to eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing. The Company’s obligations under this Note are secured by a lien on the assets of the Company.</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">On January 14, 2019, the Company received proceeds of $500,000 on an unsecured convertible promissory note that carries a 6% interest rate from The Sanguine Group LLC. The Note was due January 14, 2022. In the event that the Company consummated the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest would automatically be converted into such equity securities at a conversion price equal to the lesser of (i) eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing, or (ii) $0.424 per share. The Company’s obligations under this Note were secured by a lien on the assets of the Company. A Qualified Financing subsequently occurred on February 4, 2019, at which time the principal and interest were converted into 1,253,493 shares of the Company’s common stock.</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less: unamortized debt discounts</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Convertible note payable</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Notes payable consists of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font-family: Times New Roman, Times, Serif">On December 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">100,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">100,000</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">On November 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">100,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">100,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Total notes payable</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

The components of lease expense were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">For the Six Months Ended</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Finance lease cost:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 73%; text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Amortization of assets</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 23%; text-align: right; font-family: Times New Roman, Times, Serif">19,971</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Interest on lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">9,158</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Total lease cost</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">29,129</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

The Company’s maturities of lease liabilities under finance leases as of June 30, 2019 are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">Finance</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Leases</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 78%; text-align: justify; font-family: Times New Roman, Times, Serif">2019</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 18%; text-align: right; font-family: Times New Roman, Times, Serif">27,234</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2020</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">55,824</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2021</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">57,498</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2022</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">59,223</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">2023</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">61,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Thereafter</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">51,957</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; text-indent: 8.25pt; font-family: Times New Roman, Times, Serif">Total</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">312,876</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less interest</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">56,461</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; text-indent: 8.25pt; font-family: Times New Roman, Times, Serif">Present value of lease liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Less current portion</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">38,561</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: 8.25pt; font-family: Times New Roman, Times, Serif">Long-term lease liabilities</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">222,358</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Supplemental balance sheet information related to leases were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Finance lease:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 73%; text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Right-of-use asset</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 23%; text-align: right; font-family: Times New Roman, Times, Serif">278,725</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Accumulated amortization</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(19,971</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Right-of-use asset, net</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">258,754</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Current portion of finance lease liability</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="text-align: right; font-family: Times New Roman, Times, Serif">38,561</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Long-term finance lease liability</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">222,358</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total finance lease liability</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Weighted average remaining lease term:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Operating leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">N/A</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Finance leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">5.5 years</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Weighted average discount rate:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Operating leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">N/A</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Finance leases</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">6.75</td><td style="text-align: left; font-family: Times New Roman, Times, Serif">%</td></tr></table> Supplemental cash flow and other information related to leases was as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif">For the Six Months Ended</td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 73%; text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Operating cash flows used for finance leases</td><td style="width: 2%; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 23%; border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">26,964</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Leased assets obtained in exchange for lease liabilities:</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total finance lease liabilities</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

100000

500000

125000

100000

0.50

250000

0.424

0.50

0.06

307141

500000

200000

212385

125846

258754

212385

125846

258754

300000

307141 514141

200000

260919

-568060

-514141

-500000

212385

125846

-309306

-514141

-500000

4518

4494

67350

30850

64911

713932

356439

720898

358400

23469

18314

32216

23595

17654

156909

316491

310919

179731

6966

1961

273

27258

12924

11936 8514

6232

6387

53681

6327

125000

10323

5951

1397

125000

300000

1:4 split

500000

0.80

2022-01-14

1253493

12457

1761

100000

Parent Subsidiary Subsidiary

19971

9158

29129

278725

258754

260919

P0Y

P5Y6M

0.00

0.0675

26964

260919

56461

3900000

200000

285000

1059000

1950000

100000

142500

529500

0.50

0.42

0.50

8333

41666

8337

41674

10416

10424

8333

8337

2038

Note 1 – Nature of Business and Significant Accounting Policies   Nature of Business   One World Pharma, Inc. (formerly Punto Group, Corp.) was incorporated in Nevada on September 2, 2014. On February 21, 2019, One World Pharma, Inc. (“One World Pharma,” the “Company,” “we,” “our” or “us”) entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma SAS, a Colombian company (“OWP Colombia”). Pursuant to the Merger Agreement, we acquired OWP Ventures (and indirectly, OWP Colombia) by the merger of OWP Merger Subsidiary with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary (the “Merger”). As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors. The Company’s headquarters are located in Las Vegas, Nevada, and all of its customers are expected to be outside of the United States. On January 10, 2019, the Company changed its name from Punto Group, Corp. to One World Pharma, Inc.   OWP Ventures is a holding company formed in Delaware on March 27, 2018 to enter and support the cannabis industry, and on May 30, 2018, it acquired OWP Colombia. OWP Colombia is a licensed cannabis cultivation, production and distribution (export) company located in Popayán, Colombia (nearest major city is Cali). We plan to be a producer of raw cannabis and hemp plant ingredients for both medical and industrial uses across the globe. We have received licenses to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes. Specifically, we are one of the only companies in Colombia to receive seed, cultivation, extraction and export licenses from the Colombian government. Currently, we own approximately 30 acres and have a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we have entered into agreements with local farming co-operatives that include small farmers and indigenous tribe members, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We planted our first crop of cannabis in 2018, which we began harvesting in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced. To date, we have not yet generated any revenues from our activities.   The Merger was accounted for as a reverse merger (recapitalization) with OWP Ventures deemed to be the accounting acquirer. Accordingly, the financial statements included in this Quarterly Report on Form 10-Q reflect the historical operations of OWP Ventures and its wholly-owned subsidiary OWP SAS prior to the Merger, and that of the combined company following the Merger. The historical financial information for One World Pharma, Inc. (formerly Punto Group Corp.) prior to the Merger has been omitted.   Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated.   The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and Current Report on Form 8-K with respect to the Merger originally filed with the SEC on February 25, 2019, as amended and restated on July 12, 2019. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K and Current Report on Form 8-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.   Principles of Consolidation   The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: center; font-family: Times New Roman, Times, Serif">State of</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Name of Entity</td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif">Incorporation</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 16%; border-bottom: Black 1.5pt solid; text-align: center; font-family: Times New Roman, Times, Serif">Relationship</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">One World Pharma, Inc.(1)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Nevada</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Parent</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">OWP Ventures, Inc.(2)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Delaware</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Subsidiary</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif">One World Pharma S.A.S.(3)</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Colombia</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif">Subsidiary</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> </table>   (1)Holding company in the form of a corporation. (2)Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.  (3)Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogotá on July 18, 2017. Its headquarters are located in Bogotá.   The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. The Company's headquarters are located in Las Vegas, Nevada and substantially all of its production efforts are within Popayán, Colombia.   Foreign Currency Translation   The functional currency of the Company is Columbian Peso (COP). The Company has maintained its financial statements using the functional currency, and translated those financial statements to the US Dollar (USD) throughout this report. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods.   Comprehensive Income   The Company has adopted ASC 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Segment Reporting   ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.   Fair Value of Financial Instruments   Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short term nature of the instruments.   Cash and Cash Equivalents   Cash and cash equivalents include cash on hand, cash on deposit with various financial institutions in Columbia, and all highly-liquid investments with original maturities of three months or less at the time of purchase. We have not held any cash equivalents to date.   Cash in Excess of FDIC Insured Limits   The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. The Company didn’t have any amounts in excess of FDIC insured limits at June 30, 2019, and has not experienced any losses in such accounts.   Revenue Recognition   The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of commercial sales of products, licensing agreements and contracts. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition.   There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the six months ended June 30, 2019, or the year ended December 31, 2018.   Inventory   Inventories are stated at the lower of cost or market. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our cannabis products consist of cannabis flower grown in-house, along with produced extracts.   Stock-Based Compensation   The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty's performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.   Basic and Diluted Loss Per Share   The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.   Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements   In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its financial statements.   In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. The Company is currently in the process of evaluating the impact of adoption on its financial statements.    In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its financial statements.   In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.   The new standard became effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company adopted the new standard on January 1, 2019 using the modified retrospective transition approach as of the effective date of the initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.   The most significant effects of the adoption of the new standard relate to the recognition of new ROU assets and lease labilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities.   The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has also elected the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities, for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and non-lease components for its leases. The new standard did not have a material impact.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted the new standard to be effective upon inception. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, adoption does not have a material impact on our financial position, results of operations, or cash flows. Related disclosures have been expanded in line with the requirements of the standard.   There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Note 2 –Going Concern   As shown in the accompanying condensed consolidated financial statements as of June 30, 2019, the Company has cash on hand of $212,385, a working capital deficit of $745,796 and an accumulated deficit of $4,608,726, and the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing its cannabis cultivation activities and expects to begin revenue generating export operations in the first quarter of 2020. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   The condensed consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 – Related Party Transactions   Repayment and Exchanges of Advances from Shareholders   A total of $207,000 of demand notes owed to our CEO was repaid over various dates from March of 2019 through May of 2019.   On various dates between October 25, 2018 and November 23, 2018, our CEO advanced funds to the Company totaling $307,141 under short-term unsecured demand loans, bearing interest at 6% per annum. On February 13, 2019, these promissory notes were exchanged for an amended and restated promissory note in the principal amount of $307,141 that bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.

Note 5 – Fair Value of Financial Instruments   Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.   The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.</td></tr> </table>   The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheet as of June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Fair Value Measurements at June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 1</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 2</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 3</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Assets</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 46%; font-family: Times New Roman, Times, Serif">Cash</td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif">212,385</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Right-of-use asset</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">258,754</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total assets</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">212,385</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">258,754</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Convertible note payable</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Advances from shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">307,141</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Notes payable</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Lease liability</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">260,919</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total liabilities</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(568,060</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">212,385</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(309,306</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Fair Value Measurements at December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 1</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 2</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">Level 3</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; background-color: rgb(204,255,204)"> <td style="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif">Assets</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="width: 46%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Cash</td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">125,846</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 14%; border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total assets</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">125,846</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="font-weight: bold; padding-left: 20pt; text-align: center; font-family: Times New Roman, Times, Serif">Liabilities</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Convertible note payable</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">300,000</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; font-family: Times New Roman, Times, Serif">Advances from shareholders</td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">514,141</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">Notes payable</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">200,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif">Total liabilities</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(514,141</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">125,846</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(514,141</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">(500,000</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif">)</td></tr> </table>   There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2019 or the year ended December 31, 2018.

Note 13 – Changes in Stockholders’ Equity   One World Pharma is authorized to issue an aggregate of 75,000,000 shares of common stock with a par value of $0.001. As of June 30, 2019, there were 39,922,899 shares of common stock issued and outstanding. The par value of OWP Ventures’ common stock was $0.0001 per share. The par value presented for OWP Ventures’ transactions have been retroactively adjusted to reflect the par value of One World Pharma in this Quarterly Report on Form 10-Q.   Reverse Stock Split   On January 10, 2019, One World Pharma, Inc. effected a 1-for-4 reverse stock split. No fractional shares were issued, and no cash or other consideration was paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. One World Pharma, Inc. was authorized to issue 75,000,000 shares of common stock prior to the Reverse Stock Split, which remains unaffected. The Reverse Stock Split did not have any effect on the stated par value of the common stock. Unless otherwise stated, all share and per share information in this Quarterly Report on Form 10-Q has been retroactively adjusted to reflect the Reverse Stock Split.   Cash Received on Subscriptions Receivable   On various dates between January 30, 2019 and February 5, 2019, the Company received $602 from two of the Company’s founders for sales of common stock of OWP Ventures during 2018 at $0.001 per share on subscriptions receivable.   Common Stock Sales   On various dates between January 3, 2019 and February 19, 2019, the Company sold an aggregate 3,900,000 shares of common stock of OWP Ventures at $0.50 per share for total proceeds of $1,950,000.   Common Stock Issued for Debt Conversion   On February 4, 2019, a total of 1,253,493 shares of common stock of OWP Ventures were issued pursuant to the conversion of $501,397 of convertible debt owed to The Sanguine Group LLC, consisting of $500,000 of principal and $1,397 of interest.   Common Stock Issued for Services   On February 18, 2019, the Company issued 30,000 shares of common stock of OWP Ventures to a consultant for services. The total fair value of the common stock was $15,000 based recent independent third-party sales at $0.50 per share.    Common Stock Options Issued for Services   On February 8, 2019, the Company awarded cashless options to a service provider to acquire up to 100,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 8,333 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 8,337 shares on the one-year anniversary of the effective date.   On February 8, 2019, the Company awarded cashless options to one of our directors to acquire up to 125,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 10,416 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 10,424 shares on the one-year anniversary of the effective date.   On January 28, 2019, the Company awarded cashless options to a service provider to acquire up to 500,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 41,666 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 41,674 shares on the one-year anniversary of the effective date.   On January 28, 2019, the Company awarded cashless options to a service provider to acquire up to 100,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 8,333 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 8,337 shares on the one-year anniversary of the effective date.   On October 24, 2018, the Company issued 50,000 shares of common stock of OWP Ventures to a consultant in settlement for services. The total fair value of the common stock was $21,000 based recent independent third-party sales at $0.42 per share.   A total of $560,958 was expensed during the six months ending June 30, 2019 pursuant to the options issued for services.   Common Stock Issued for Share Exchange   On February 21, 2019, One World Pharma acquired OWP Ventures in the Merger. As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) the options described above to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; and (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled.

Note 14 – Income Taxes   The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.   For the six months ended June 30, 2019 and the year ended December 31, 2018, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At June 30, 2019, the Company had approximately $3,681,600 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2038.   Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at June 30, 2019 and December 31, 2018, respectively.   In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Note 15 – Subsequent Events   Common Stock Sales   On August 12, 2019, the Company sold 1,059,000 shares of common stock at $0.50 per share for proceeds of $529,500.   On July 29, 2019, the Company sold 200,000 shares of common stock at $0.50 per share for proceeds of $100,000.   On July 17, 2019, the Company sold 285,000 shares of common stock at $0.50 per share for proceeds of $142,500.   Debt Exchange   On July 22, 2019, the Company exchanged two outstanding demand notes bearing 6% interest (See Note 11), in the aggregate amount of $207,332, consisting of $200,000 of principal and $7,332 of accrued interest, for a convertible promissory note in the principal amount of $207,332, bearing 6% interest, due on demand and convertible into common stock at a fixed conversion price of $0.50 per share.

Advances from shareholders consist of the following at June 30, 2019 and December 31, 2018, respectively:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font-family: Times New Roman, Times, Serif">On various dates between May 3, 2018 and November 23, 2018, our CEO advanced short-term unsecured demand loans, bearing interest at 6% per annum, of an aggregate $514,141 to the Company, as follows:     $ 10,000 – May 3, 2018     $100,000 – May 3, 2018     $ 82,000 – May 14, 2018     $ 15,000 – May 29, 2018     $ 57,141 – October 25, 2018     $100,000 – October 30, 2018     $ 50,000 – November 9, 2018     $ 50,000 – November 21, 2018     $ 50,000 – November 23, 2018 A total of $207,000 was repaid over various dates from March of 2019 through May of 2019, and $307,141 was exchanged for the note described below. </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="width: 2%; font-family: Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif">514,141</td><td style="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">On February 13, 2019, a total of $307,141 of the advances from our CEO received from October 25, 2018 to November 23, 2018, as shown above, were exchanged for an amended and restated promissory note in the principal amount of $307,141 (the “Amended Note”). The Amended Note bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">307,141</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: right; font-family: Times New Roman, Times, Serif"> </td><td style="text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif">Total advances from shareholders</td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">307,141</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif">$</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif">514,141</td><td style="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"> </td></tr></table>

Nature of Business   One World Pharma, Inc. (formerly Punto Group, Corp.) was incorporated in Nevada on September 2, 2014. On February 21, 2019, One World Pharma, Inc. (“One World Pharma,” the “Company,” “we,” “our” or “us”) entered into an Agreement and Plan of Merger with OWP Merger Subsidiary, Inc., our wholly-owned subsidiary, and OWP Ventures, Inc. (“OWP Ventures”), which is the parent company of One World Pharma SAS, a Colombian company (“OWP Colombia”). Pursuant to the Merger Agreement, we acquired OWP Ventures (and indirectly, OWP Colombia) by the merger of OWP Merger Subsidiary with and into OWP Ventures, with OWP Ventures being the surviving entity as our wholly-owned subsidiary (the “Merger”). As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future “Qualified Offering”; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures’ chief operating officer became our chief operating officer and two of OWP Ventures’ directors became members of our board of directors. The Company’s headquarters are located in Las Vegas, Nevada, and all of its customers are expected to be outside of the United States. On January 10, 2019, the Company changed its name from Punto Group, Corp. to One World Pharma, Inc.   OWP Ventures is a holding company formed in Delaware on March 27, 2018 to enter and support the cannabis industry, and on May 30, 2018, it acquired OWP Colombia. OWP Colombia is a licensed cannabis cultivation, production and distribution (export) company located in Popayán, Colombia (nearest major city is Cali). We plan to be a producer of raw cannabis and hemp plant ingredients for both medical and industrial uses across the globe. We have received licenses to cultivate, produce and distribute the raw ingredients of the cannabis and hemp plant for medicinal, scientific and industrial purposes. Specifically, we are one of the only companies in Colombia to receive seed, cultivation, extraction and export licenses from the Colombian government. Currently, we own approximately 30 acres and have a covered greenhouse built specifically to cultivate high-grade cannabis and hemp. In addition, we have entered into agreements with local farming co-operatives that include small farmers and indigenous tribe members, under which they will cultivate cannabis on up to approximately 140 acres of land using our seeds and propagation techniques, and sell their harvested products to us on an exclusive basis. We planted our first crop of cannabis in 2018, which we began harvesting in the first quarter of 2019 for the purpose of further research and development activities and quality control testing of the cannabis we have produced. To date, we have not yet generated any revenues from our activities.   The Merger was accounted for as a reverse merger (recapitalization) with OWP Ventures deemed to be the accounting acquirer. Accordingly, the financial statements included in this Quarterly Report on Form 10-Q reflect the historical operations of OWP Ventures and its wholly-owned subsidiary OWP SAS prior to the Merger, and that of the combined company following the Merger. The historical financial information for One World Pharma, Inc. (formerly Punto Group Corp.) prior to the Merger has been omitted.

Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated.   The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and Current Report on Form 8-K with respect to the Merger originally filed with the SEC on February 25, 2019, as amended and restated on July 12, 2019. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K and Current Report on Form 8-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Segment Reporting   ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

Fair Value of Financial Instruments   Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short term nature of the instruments.

Cash and Cash Equivalents   Cash and cash equivalents include cash on hand, cash on deposit with various financial institutions in Columbia, and all highly-liquid investments with original maturities of three months or less at the time of purchase. We have not held any cash equivalents to date.

Revenue Recognition   The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of commercial sales of products, licensing agreements and contracts. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition.   There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the six months ended June 30, 2019, or the year ended December 31, 2018.

Stock-Based Compensation   The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty's performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.

Basic and Diluted Loss Per Share   The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements   In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its financial statements.   In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. The Company is currently in the process of evaluating the impact of adoption on its financial statements.    In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The Company does not expect the adoption of this ASU to have a material impact on its financial statements.   In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created by leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.   The new standard became effective January 1, 2019. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. If an entity chooses the second option, the transition requirements for existing leases also apply to leases entered into between the date of initial application and the effective date. The entity must also recast its comparative period financial statements and provide the disclosures required by the new standard for the comparative periods. The Company adopted the new standard on January 1, 2019 using the modified retrospective transition approach as of the effective date of the initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits entities not to reassess under the new lease standard prior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to elect the use-of-hindsight or the practical expedient pertaining to land easements.   The most significant effects of the adoption of the new standard relate to the recognition of new ROU assets and lease labilities on our balance sheet for office operating leases and providing significant new disclosures about our leasing activities.   The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has also elected the short-term leases recognition exemption for all leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets and lease liabilities, for existing short-term leases of those assets in transition. The Company also currently expects to elect the practical expedient to not separate lease and non-lease components for its leases. The new standard did not have a material impact.   In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers. Since ASU 2014-09 was issued, several additional ASUs have been issued to clarify various elements of the guidance. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted the new standard to be effective upon inception. We have completed an initial evaluation of the potential impact from adopting the new standard, including a detailed review of performance obligations for all material revenue streams. Based on this initial evaluation, adoption does not have a material impact on our financial position, results of operations, or cash flows. Related disclosures have been expanded in line with the requirements of the standard.   There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

110741

24978

258754

69542

13092

74074

-652131

248

147

-159535

-1801

-18519

-1801

5005

103

125000

0.0499

3681600

19971

Inventory   Inventories are stated at the lower of cost or market. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method. Market is determined based on net realizable value. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. Our cannabis products consist of cannabis flower grown in-house, along with produced extracts.

Yes Yes

-4087

143001

35402

86539

444920

212385

125846

444920

74074

-652030

34292

39923

1278352

4503966

-1959982

-4608726

-602

-4090

-101

138911

34291905

39922899

125000

75000

3900000 1950000 3900 1946100

1253493

501397

1253

500144

30000 15000 30 14970 88297 88297

1322501

-9306

1323

-10730

101

-875

875

560958 560958

1416370

517629

5000000

38561

222358

0.50

207332

7332

560958

39475398

825000

0.50

As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future "Qualified Offering"; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures' chief operating officer became our chief operating officer and two of OWP Ventures' directors became members of our board of directors.

NV DE F8

-2505743

-248216

-1173940

-283618

207000

false -349420 -349420

23412

978703

-602

1001513

10200

152709

162909

10200000

136440

745796

155696

1801

14579

1801

5951

125000 1965 40

27234

55824

57498

59223

61000

51957

312876

The Company recognized interest expense for the six months ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018, respectively, as follows:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2019</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">June 30, 2018</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(205,255,205); font: 10pt Times New Roman, Times, Serif"> <td style="width: 60%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Interest on convertible notes</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif">10,323</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif">-</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Interest on advances from shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">12,457</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,761</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(205,255,205); font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Interest on notes payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5,951</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">-</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Amortization of beneficial conversion features</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">125,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">-</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(205,255,205); font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Interest on accounts payable</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,965</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Total interest expense</td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">155,696</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td><td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,801</td><td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"> </td></tr></table> Holding company in the form of a corporation. Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc. Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogota on July 18, 2017. Its headquarters are located in Bogota.

EX-101.SCH 6 owpc-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Reverse Merger link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Convertible Note Payable link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Advances from Shareholders link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Convertible Note Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Advances from Shareholders (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Common Control and Ownership Interest (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Reverse Merger (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Fair Value of Financial Instruments - Schedule of Valuation of Financial Instruments at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Fixed Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Fixed Assets - Schedule of Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Convertible Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Advances from Shareholders (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Advances from Shareholders - Schedule of Advances from Shareholders (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Advances from Shareholders - Schedule of Advances from Shareholders (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Notes Payable - Schedule of Interest Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Leases - Schedule of Supplemental Cash Flow Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Leases - Schedule of Finance Lease Liability Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Changes in Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 owpc-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 owpc-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 owpc-20190630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Merger Agreement [Member] Legal Entity [Axis] OWP Ventures, Inc. [Member] Subscriptions Receivable [Member] Accumulated Other Comprehensive Income (Loss) [Member] Noncontrolling Interest [Member] Title of Individual [Axis] CEO [Member] Debt Instrument [Axis] Promissory Notes [Member] Fair Value Hierarchy and NAV [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Property, Plant and Equipment, Type [Axis] Office Equipment [Member] Furniture and Fixtures [Member] Software [Member] Construction in Progress [Member] Convertible Note Payable One [Member] Convertible Note Payable Two [Member] CSW Ventures, LP [Member] Short-Term Unsecured Demand Loans One[Member] Short-Term Unsecured Demand Loans Two [Member] Short-Term Unsecured Demand Loans [Member] Notes Payable [Member] Notes Payable One [Member] Notes Payable Two [Member] Unsecured Promissory Note [Member] One World Pharma, Inc [Member] One World Pharma S.A.S. [Member] Service Provider [Member] Scenario [Axis] One-Year Anniversary [Member] Director [Member] Service Provider One [Member] Consultant [Member] Sanguine Group LLC [Member] Equipment and machinery [Member] Land [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Convertible Promissory Notes [Member] Two Outstanding Demand Notes [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash Other current assets Inventory Total current assets Right-of-use asset Security deposits Fixed assets, net Total Assets Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable Accrued expenses Current portion of lease liability Convertible note payable Advances from shareholders Notes payable Total current liabilities Long-term lease liability Total Liabilities Stockholders' Equity (Deficit): Common stock, $0.001 par value, 75,000,000 shares authorized; 39,922,899 and 34,291,905 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively Additional paid-in capital Subscriptions receivable, consisting of 6,012,500 shares at December 31, 2018 Accumulated other comprehensive loss Accumulated (deficit) Total Stockholders' Equity Noncontrolling Interest Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Subscriptions receivable, shares Income Statement [Abstract] Revenue: Operating expenses: General and administrative Professional fees Total operating expenses Operating loss Other income (expense): Loss on disposal of assets Interest income Interest expense Total other expense Net loss Other comprehensive loss: Gain on foreign currency translation Net other comprehensive loss Weighted average number of common shares outstanding - basic and fully diluted Net loss per share - basic and fully diluted Statement [Table] Statement [Line Items] Balance Balance, shares Consolidation of One World Pharma, Inc. Common stock sold for cash Common stock sold for cash, shares Common stock issued for services Common stock issued for services, shares Common stock issued for purchase of One World Pharma S.A.S. Common stock issued for purchase of One World Pharma S.A.S, shares Contributed capital Beneficial conversion feature on convertible note Gain (loss) on foreign currency translation Cash received on subscriptions receivable of OWP Ventures, Inc. Common stock of OWP Ventures, Inc. sold for cash Common stock of OWP Ventures, Inc. sold for cash, shares Issuance of common stock of OWP Ventures, Inc. on debt conversion Issuance of common stock of OWP Ventures, Inc. on debt conversion, shares Common stock issued for services, OWP Ventures, Inc Common stock issued for services, OWP Ventures, Inc, shares Amortization of common stock options issued for services, OWP Ventures, Inc Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1) Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1), shares Common stock cancelled pursuant to merger with OWP Ventures, Inc Common stock cancelled pursuant to merger with OWP Ventures, Inc, shares Amortization of common stock options issued for services Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense Loss on disposal of fixed assets Debt discounts Stock-based compensation Amortization of options issued for services Decrease (increase) in assets: Other current assets Inventory Right-of-use assets Security deposits Increase (decrease) in liabilities: Accounts payable Accrued expenses Lease liability Net cash used in operating activities Cash flows from investing activities Purchase of fixed assets Net cash used in investing activities Cash flows from financing activities Proceeds from convertible note payable Proceeds from shareholders Repayment of advances from shareholders Proceeds from subscriptions receivable Proceeds from sale of common stock Net cash provided by financing activities Effect of exchange rate changes on cash Net increase in cash Cash - beginning Cash - ending Supplemental disclosures: Interest paid Income taxes paid Non-cash investing and financing transactions: Fair value of net assets acquired in merger Value of shares issued for conversion of debt Beneficial conversion feature Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business and Significant Accounting Policies Going Concern Business Combinations [Abstract] EX-101.PRE 10 owpc-20190630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 12, 2019
Document And Entity Information
Entity Registrant Name	One World Pharma, Inc.
Entity Central Index Key	0001622244
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		41,466,899
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 212,385	$ 125,846
Other current assets	136,779	35,344
Inventory	24,978
Total current assets	374,142	161,190
Right-of-use asset	258,754
Security deposits	69,542
Fixed assets, net	713,932	356,439
Total Assets	1,416,370	517,629
Current liabilities:
Accounts payable	175,129	121,194
Accrued expenses	99,107	34,425
Current portion of lease liability	38,561
Convertible note payable	300,000	300,000
Advances from shareholders	307,141	514,141
Notes payable	200,000	200,000
Total current liabilities	1,119,938	1,169,760
Long-term lease liability	222,358
Total Liabilities	1,342,296	1,169,760
Stockholders' Equity (Deficit):
Common stock, $0.001 par value, 75,000,000 shares authorized; 39,922,899 and 34,291,905 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	39,923	34,292
Additional paid-in capital	4,503,966	1,278,352
Subscriptions receivable, consisting of 6,012,500 shares at December 31, 2018		(602)
Accumulated other comprehensive loss	138,911	(4,090)
Accumulated (deficit)	(4,608,726)	(1,959,982)
Total Stockholders' Equity	74,074	(652,030)
Noncontrolling Interest		(101)
Total Stockholders' Equity (Deficit)	74,074	(652,131)
Total Liabilities and Stockholders' Equity (Deficit)	$ 1,416,370	$ 517,629

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	39,922,899	34,291,905
Common stock, shares outstanding	39,922,899	34,291,905
Subscriptions receivable, shares		6,012,500

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2019
Income Statement [Abstract]
Revenue:
Operating expenses:
General and administrative	565,167	124,840	124,840	1,044,787
Professional fees	741,542	156,977	156,977	1,444,422
Total operating expenses	1,306,709	281,817	281,817	2,489,209
Operating loss	(1,306,709)	(281,817)	(281,817)	(2,489,209)
Other income (expense):
Loss on disposal of assets	(4,087)			(4,087)
Interest income	147			248
Interest expense	(14,579)	(1,801)	(1,801)	(155,696)
Total other expense	(18,519)	(1,801)	(1,801)	(159,535)
Net loss	(1,325,228)	(283,618)	(283,618)	(2,648,744)
Other comprehensive loss:
Gain on foreign currency translation	151,288	35,402		143,001
Net other comprehensive loss	$ (1,173,940)	$ (248,216)	$ (283,618)	$ (2,505,743)
Weighted average number of common shares outstanding - basic and fully diluted	39,922,899	29,410,501	29,777,996	38,779,975
Net loss per share - basic and fully diluted	$ (0.03)	$ (0.01)	$ (0.01)	$ (0.06)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Subscriptions Receivable [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Mar. 26, 2018
Balance, shares at Mar. 26, 2018
Consolidation of One World Pharma, Inc.		(349,420)					(349,420)
Common stock sold for cash	$ 23,412	978,703	(602)				1,001,513
Common stock sold for cash, shares	23,411,905
Common stock issued for services	$ 680	284,920					285,600
Common stock issued for services, shares	680,000
Common stock issued for purchase of One World Pharma S.A.S.	$ 10,200	152,709					162,909
Common stock issued for purchase of One World Pharma S.A.S, shares	10,200,000
Contributed capital		136,440					136,440
Beneficial conversion feature on convertible note		75,000					75,000
Gain (loss) on foreign currency translation				(4,090)			(4,090)
Net loss					(1,959,982)	(101)	(1,960,083)
Balance at Dec. 31, 2018	$ 34,292	1,278,352	(602)	(4,090)	(1,959,982)	(101)	(652,030)
Balance, shares at Dec. 31, 2018	34,291,905
Beneficial conversion feature on convertible note		125,000					125,000
Gain (loss) on foreign currency translation				143,001			143,001
Cash received on subscriptions receivable of OWP Ventures, Inc.			602				602
Common stock of OWP Ventures, Inc. sold for cash	$ 3,900	1,946,100					1,950,000
Common stock of OWP Ventures, Inc. sold for cash, shares	3,900,000
Issuance of common stock of OWP Ventures, Inc. on debt conversion	$ 1,253	500,144					501,397
Issuance of common stock of OWP Ventures, Inc. on debt conversion, shares	1,253,493
Common stock issued for services, OWP Ventures, Inc	$ 30	14,970					15,000
Common stock issued for services, OWP Ventures, Inc, shares	30,000
Amortization of common stock options issued for services, OWP Ventures, Inc		88,297					88,297
Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1)	$ 1,323	(10,730)				101	(9,306)
Exchange of OWP Ventures, Inc. shares for One World Pharma, Inc. shares (1:1), shares	1,322,501
Common stock cancelled pursuant to merger with OWP Ventures, Inc	$ (875)	875
Common stock cancelled pursuant to merger with OWP Ventures, Inc, shares	(875,000)
Amortization of common stock options issued for services		560,958					560,958
Net loss					(2,648,744)		(2,648,744)
Balance at Jun. 30, 2019	$ 39,923	$ 4,503,966		$ 138,911	$ (4,608,726)		$ 74,074
Balance, shares at Jun. 30, 2019	39,922,899

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (1,325,228)	$ (283,618)	$ (283,618)	$ (2,648,744)	$ (1,960,083)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		103		5,005
Loss on disposal of fixed assets	4,087			4,087
Debt discounts				125,000	75,000
Stock-based compensation				15,000
Amortization of options issued for services				649,255
Decrease (increase) in assets:
Other current assets				(110,741)
Inventory				(24,978)
Right-of-use assets				(258,754)
Security deposits		(13,092)		(69,542)
Increase (decrease) in liabilities:
Accounts payable		7,957		53,935
Accrued expenses		2,753		66,079
Lease liability				260,919
Net cash used in operating activities		(285,897)		(1,933,479)
Cash flows from investing activities
Purchase of fixed assets		(11,585)		(366,585)
Net cash used in investing activities		(11,585)		(366,585)
Cash flows from financing activities
Proceeds from convertible note payable				500,000
Proceeds from shareholders		207,000
Repayment of advances from shareholders				(207,000)
Proceeds from subscriptions receivable				602
Proceeds from sale of common stock		500,000		1,950,000
Net cash provided by financing activities		707,000		2,243,602
Effect of exchange rate changes on cash		35,402		143,001
Net increase in cash		444,920		86,539
Cash - beginning				125,846
Cash - ending	$ 212,385	444,920	$ 444,920	212,385	$ 125,846
Supplemental disclosures:
Interest paid				14,965
Income taxes paid
Non-cash investing and financing transactions:
Fair value of net assets acquired in merger				9,306
Value of shares issued for conversion of debt				501,397
Beneficial conversion feature				$ 125,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business and Significant Accounting Policies

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

Basis of Presentation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:

	State of
Name of Entity	Incorporation	Relationship
One World Pharma, Inc.⁽¹⁾	Nevada	Parent
OWP Ventures, Inc.⁽²⁾	Delaware	Subsidiary
One World Pharma S.A.S.⁽³⁾	Colombia	Subsidiary

⁽¹⁾Holding company in the form of a corporation.

⁽²⁾Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.

Foreign Currency Translation

Comprehensive Income

Use of Estimates

Segment Reporting

Fair Value of Financial Instruments

Cash and Cash Equivalents

Cash in Excess of FDIC Insured Limits

Revenue Recognition

There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the six months ended June 30, 2019, or the year ended December 31, 2018.

Inventory

Stock-Based Compensation

Basic and Diluted Loss Per Share

Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements

XML 18 R8.htm IDEA: XBRL DOCUMENT

Going Concern

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

Note 2 –Going Concern

XML 19 R9.htm IDEA: XBRL DOCUMENT

Reverse Merger

6 Months Ended

Jun. 30, 2019

Business Combinations [Abstract]

Reverse Merger

Note 3 – Reverse Merger

XML 20 R10.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2019

Related Party Transactions

Note 4 – Related Party Transactions

Repayment and Exchanges of Advances from Shareholders

A total of $207,000 of demand notes owed to our CEO was repaid over various dates from March of 2019 through May of 2019.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2019

Investments, All Other Investments [Abstract]

Fair Value of Financial Instruments

Note 5 – Fair Value of Financial Instruments

	Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

	Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

	Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheet as of June 30, 2019 and December 31, 2018, respectively:

	Fair Value Measurements at June 30, 2019
	Level 1		Level 2			Level 3
Assets
Cash	$	212,385	$	-		$	-
Right-of-use asset		-		258,754			-
Total assets		212,385		258,754			-
Liabilities
Convertible note payable		-		-			300,000
Advances from shareholders		-		307,141			-
Notes payable		-		-			200,000
Lease liability		-		260,919			-
Total liabilities		-		(568,060	)		(500,000	)
	$	212,385	$	(309,306	)	$	(500,000	)

	Fair Value Measurements at December 31, 2018
	Level 1		Level 2			Level 3
Assets
Cash	$	125,846	$	-		$	-
Total assets		125,846		-			-
Liabilities
Convertible note payable		-		-			300,000
Advances from shareholders		-		514,141			-
Notes payable		-		-			200,000
Total liabilities		-		(514,141	)		(500,000	)
	$	125,846	$	(514,141	)	$	(500,000	)

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended June 30, 2019 or the year ended December 31, 2018.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Other Current Assets

6 Months Ended

Jun. 30, 2019

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

Note 6 – Other Current Assets

Other current assets included the following as of June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018
Security deposit	$	4,518	$	4,494
Prepaid expenses		67,350		30,850
Other receivables		64,911		-
Total	$	136,779	$	35,344

XML 23 R13.htm IDEA: XBRL DOCUMENT

Fixed Assets

6 Months Ended

Jun. 30, 2019

Property, Plant and Equipment [Abstract]

Fixed Assets

Note 7 – Fixed Assets

Fixed assets consist of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019			December 31, 2018
Land	$	179,731		$	-
Office equipment		23,469			18,314
Furniture and fixtures		32,216			23,595
Software		17,654			-
Equipment and machinery		310,919			-
Construction in progress		156,909			316,491
		720,898			358,400
Less: accumulated depreciation		(6,966	)		(1,961	)
Total	$	713,932		$	356,439

Construction in progress consists of equipment and capital improvements on the Popayán farm that have not yet been placed in service.

Depreciation and amortization expense totaled $5,005 and $103 for the six months ended June 30, 2019 and June 30, 2018, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Accrued Expenses

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Accrued Expenses

Note 8 – Accrued Expenses

Accrued expenses consisted of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018
Accrued payroll	$	53,681	$	6,327
Accrued withholding taxes		6,232		6,387
Accrued ICA fees and contributions		11,936		8,514
Accrued interest		27,258		12,924
Deferred rent obligations		-		273
	$	99,107	$	34,425

XML 25 R15.htm IDEA: XBRL DOCUMENT

Convertible Note Payable

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Convertible Note Payable

Note 9 – Convertible Note Payable

Convertible note payable consists of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On November 30, 2018, the Company received proceeds of $300,000 on a secured convertible note that carries a 6% interest rate from CSW Ventures, LP (“CSW”). The proceeds were used to fund the Company’s purchase of 875,000 shares of common stock, on a 1:4 split adjusted basis, of One World Pharma, Inc. The Note is due on demand. In the event that the Company consummates the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest may, at the option of the holder, be converted into such equity securities at a conversion price equal to eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing. The Company’s obligations under this Note are secured by a lien on the assets of the Company.	$	300,000	$	300,000

On January 14, 2019, the Company received proceeds of $500,000 on an unsecured convertible promissory note that carries a 6% interest rate from The Sanguine Group LLC. The Note was due January 14, 2022. In the event that the Company consummated the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest would automatically be converted into such equity securities at a conversion price equal to the lesser of (i) eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing, or (ii) $0.424 per share. The Company’s obligations under this Note were secured by a lien on the assets of the Company. A Qualified Financing subsequently occurred on February 4, 2019, at which time the principal and interest were converted into 1,253,493 shares of the Company’s common stock.		-		-
Less: unamortized debt discounts		-		-
Convertible note payable	$	300,000	$	300,000

The convertible note limits the maximum number of shares that can be owned by the note holder as a result of the conversions to common stock to 4.99% of the Company’s issued and outstanding shares.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Advances from Shareholders

6 Months Ended

Jun. 30, 2019

Advances from Shareholders

Note 10 – Advances from Shareholders

Advances from shareholders consist of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On various dates between May 3, 2018 and November 23, 2018, our CEO advanced short-term unsecured demand loans, bearing interest at 6% per annum, of an aggregate $514,141 to the Company, as follows: $ 10,000 – May 3, 2018 $100,000 – May 3, 2018 $ 82,000 – May 14, 2018 $ 15,000 – May 29, 2018 $ 57,141 – October 25, 2018 $100,000 – October 30, 2018 $ 50,000 – November 9, 2018 $ 50,000 – November 21, 2018 $ 50,000 – November 23, 2018 A total of $207,000 was repaid over various dates from March of 2019 through May of 2019, and $307,141 was exchanged for the note described below.	$	-	$	514,141

On February 13, 2019, a total of $307,141 of the advances from our CEO received from October 25, 2018 to November 23, 2018, as shown above, were exchanged for an amended and restated promissory note in the principal amount of $307,141 (the “Amended Note”). The Amended Note bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.		307,141		-

Total advances from shareholders	$	307,141	$	514,141

The Company recorded interest expense in the amount of $12,457 for the six months ended June 30, 2019.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Notes Payable

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Notes Payable

Note 11 – Notes Payable

Notes payable consists of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On December 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.	$	100,000	$	100,000

On November 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.		100,000		100,000

Total notes payable	$	200,000	$	200,000

The Company recorded interest expense in the amount of $5,951 for the six months ended June 30, 2019.

The Company recognized interest expense for the six months ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018, respectively, as follows:

	June 30, 2019		June 30, 2018

Interest on convertible notes	$	10,323	$	-
Interest on advances from shareholders		12,457		1,761
Interest on notes payable		5,951		-
Amortization of beneficial conversion features		125,000		-
Interest on accounts payable		1,965		40
Total interest expense	$	155,696	$	1,801

XML 28 R18.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

Note 12 – Leases

The components of lease expense were as follows:

	For the Six Months Ended
	June 30, 2019
Finance lease cost:
Amortization of assets	$	19,971
Interest on lease liabilities		9,158
Total lease cost	$	29,129

Supplemental balance sheet information related to leases were as follows:

	June 30, 2019
Finance lease:
Right-of-use asset	$	278,725
Accumulated amortization		(19,971	)
Right-of-use asset, net	$	258,754

Current portion of finance lease liability	$	38,561
Long-term finance lease liability		222,358
Total finance lease liability	$	260,919

Weighted average remaining lease term:
Operating leases		N/A
Finance leases		5.5 years

Weighted average discount rate:
Operating leases		N/A
Finance leases		6.75	%

Supplemental cash flow and other information related to leases was as follows:

	For the Six Months Ended
	June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used for finance leases	$	26,964

Leased assets obtained in exchange for lease liabilities:
Total operating lease liabilities	$	-
Total finance lease liabilities	$	260,919

The Company’s maturities of lease liabilities under finance leases as of June 30, 2019 are as follows:

	Finance
	Leases

2019	$	27,234
2020		55,824
2021		57,498
2022		59,223
2023		61,000
Thereafter		51,957
Total		312,876
Less interest		56,461
Present value of lease liabilities		260,919
Less current portion		38,561
Long-term lease liabilities	$	222,358

There were no operating leases as of June 30, 2019.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Changes in Stockholders' Equity

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Changes in Stockholders' Equity

Note 13 – Changes in Stockholders’ Equity

Reverse Stock Split

Cash Received on Subscriptions Receivable

Common Stock Sales

On various dates between January 3, 2019 and February 19, 2019, the Company sold an aggregate 3,900,000 shares of common stock of OWP Ventures at $0.50 per share for total proceeds of $1,950,000.

Common Stock Issued for Debt Conversion

Common Stock Issued for Services

Common Stock Options Issued for Services

On February 8, 2019, the Company awarded cashless options to a service provider to acquire up to 100,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 8,333 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 8,337 shares on the one-year anniversary of the effective date.

On February 8, 2019, the Company awarded cashless options to one of our directors to acquire up to 125,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 10,416 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 10,424 shares on the one-year anniversary of the effective date.

On January 28, 2019, the Company awarded cashless options to a service provider to acquire up to 500,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 41,666 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 41,674 shares on the one-year anniversary of the effective date.

On January 28, 2019, the Company awarded cashless options to a service provider to acquire up to 100,000 shares of common stock of OWP Ventures, exercisable at $0.50 per share over a thirty-six (36) month period from the origination date. The options vest as to (i) 8,333 shares on the 8th day of each subsequent month for the following eleven months, and (ii) 8,337 shares on the one-year anniversary of the effective date.

On October 24, 2018, the Company issued 50,000 shares of common stock of OWP Ventures to a consultant in settlement for services. The total fair value of the common stock was $21,000 based recent independent third-party sales at $0.42 per share.

A total of $560,958 was expensed during the six months ending June 30, 2019 pursuant to the options issued for services.

Common Stock Issued for Share Exchange

XML 30 R20.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 14 – Income Taxes

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

Note 15 – Subsequent Events

Common Stock Sales

On August 12, 2019, the Company sold 1,059,000 shares of common stock at $0.50 per share for proceeds of $529,500.

On July 29, 2019, the Company sold 200,000 shares of common stock at $0.50 per share for proceeds of $100,000.

On July 17, 2019, the Company sold 285,000 shares of common stock at $0.50 per share for proceeds of $142,500.

Debt Exchange

XML 32 R22.htm IDEA: XBRL DOCUMENT

Nature of Business and Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Nature of Business

Basis of Presentation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:

	State of
Name of Entity	Incorporation	Relationship
One World Pharma, Inc.⁽¹⁾	Nevada	Parent
OWP Ventures, Inc.⁽²⁾	Delaware	Subsidiary
One World Pharma S.A.S.⁽³⁾	Colombia	Subsidiary

⁽¹⁾Holding company in the form of a corporation.

⁽²⁾Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.

Foreign Currency Translation

Comprehensive Income

Use of Estimates

Segment Reporting

Fair Value of Financial Instruments

Cash and Cash Equivalents

Cash in Excess of FDIC Insured Limits

Revenue Recognition

There was no impact on the Company’s financial statements as a result of adopting ASC 606 for the six months ended June 30, 2019, or the year ended December 31, 2018.

Inventory

Stock-based Compensation

Stock-Based Compensation

Basic and Diluted Loss Per Share

Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements

XML 33 R23.htm IDEA: XBRL DOCUMENT

Nature of Business and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Common Control and Ownership Interest

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2019:

	State of
Name of Entity	Incorporation	Relationship
One World Pharma, Inc.⁽¹⁾	Nevada	Parent
OWP Ventures, Inc.⁽²⁾	Delaware	Subsidiary
One World Pharma S.A.S.⁽³⁾	Colombia	Subsidiary

⁽¹⁾Holding company in the form of a corporation.

⁽²⁾Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.

XML 34 R24.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2019

Investments, All Other Investments [Abstract]

Schedule of Valuation of Financial Instruments at Fair Value on a Recurring Basis

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheet as of June 30, 2019 and December 31, 2018, respectively:

	Fair Value Measurements at June 30, 2019
	Level 1		Level 2			Level 3
Assets
Cash	$	212,385	$	-		$	-
Right-of-use asset		-		258,754			-
Total assets		212,385		258,754			-
Liabilities
Convertible note payable		-		-			300,000
Advances from shareholders		-		307,141			-
Notes payable		-		-			200,000
Lease liability		-		260,919			-
Total liabilities		-		(568,060	)		(500,000	)
	$	212,385	$	(309,306	)	$	(500,000	)

	Fair Value Measurements at December 31, 2018
	Level 1		Level 2			Level 3
Assets
Cash	$	125,846	$	-		$	-
Total assets		125,846		-			-
Liabilities
Convertible note payable		-		-			300,000
Advances from shareholders		-		514,141			-
Notes payable		-		-			200,000
Total liabilities		-		(514,141	)		(500,000	)
	$	125,846	$	(514,141	)	$	(500,000	)

XML 35 R25.htm IDEA: XBRL DOCUMENT

Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2019

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets included the following as of June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018
Security deposit	$	4,518	$	4,494
Prepaid expenses		67,350		30,850
Other receivables		64,911		-
Total	$	136,779	$	35,344

XML 36 R26.htm IDEA: XBRL DOCUMENT

Fixed Assets (Tables)

6 Months Ended

Jun. 30, 2019

Property, Plant and Equipment [Abstract]

Schedule of Fixed Assets

Fixed assets consist of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019			December 31, 2018
Land	$	179,731		$	-
Office equipment		23,469			18,314
Furniture and fixtures		32,216			23,595
Software		17,654			-
Equipment and machinery		310,919			-
Construction in progress		156,909			316,491
		720,898			358,400
Less: accumulated depreciation		(6,966	)		(1,961	)
Total	$	713,932		$	356,439

XML 37 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018
Accrued payroll	$	53,681	$	6,327
Accrued withholding taxes		6,232		6,387
Accrued ICA fees and contributions		11,936		8,514
Accrued interest		27,258		12,924
Deferred rent obligations		-		273
	$	99,107	$	34,425

XML 38 R28.htm IDEA: XBRL DOCUMENT

Convertible Note Payable (Tables)

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Schedule of Convertible Note Payable

Convertible note payable consists of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On November 30, 2018, the Company received proceeds of $300,000 on a secured convertible note that carries a 6% interest rate from CSW Ventures, LP (“CSW”). The proceeds were used to fund the Company’s purchase of 875,000 shares of common stock, on a 1:4 split adjusted basis, of One World Pharma, Inc. The Note is due on demand. In the event that the Company consummates the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest may, at the option of the holder, be converted into such equity securities at a conversion price equal to eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing. The Company’s obligations under this Note are secured by a lien on the assets of the Company.	$	300,000	$	300,000

On January 14, 2019, the Company received proceeds of $500,000 on an unsecured convertible promissory note that carries a 6% interest rate from The Sanguine Group LLC. The Note was due January 14, 2022. In the event that the Company consummated the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest would automatically be converted into such equity securities at a conversion price equal to the lesser of (i) eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing, or (ii) $0.424 per share. The Company’s obligations under this Note were secured by a lien on the assets of the Company. A Qualified Financing subsequently occurred on February 4, 2019, at which time the principal and interest were converted into 1,253,493 shares of the Company’s common stock.		-		-
Less: unamortized debt discounts		-		-
Convertible note payable	$	300,000	$	300,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

Advances from Shareholders (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of Advances from Shareholders

Advances from shareholders consist of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On various dates between May 3, 2018 and November 23, 2018, our CEO advanced short-term unsecured demand loans, bearing interest at 6% per annum, of an aggregate $514,141 to the Company, as follows: $ 10,000 – May 3, 2018 $100,000 – May 3, 2018 $ 82,000 – May 14, 2018 $ 15,000 – May 29, 2018 $ 57,141 – October 25, 2018 $100,000 – October 30, 2018 $ 50,000 – November 9, 2018 $ 50,000 – November 21, 2018 $ 50,000 – November 23, 2018 A total of $207,000 was repaid over various dates from March of 2019 through May of 2019, and $307,141 was exchanged for the note described below.	$	-	$	514,141

On February 13, 2019, a total of $307,141 of the advances from our CEO received from October 25, 2018 to November 23, 2018, as shown above, were exchanged for an amended and restated promissory note in the principal amount of $307,141 (the “Amended Note”). The Amended Note bears interest at 6% and is payable upon the earlier of (i) a public or private offering of our equity securities, resulting in gross proceeds of at least $5,000,000, or (ii) February 13, 2022.		307,141		-

Total advances from shareholders	$	307,141	$	514,141

XML 40 R30.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consists of the following at June 30, 2019 and December 31, 2018, respectively:

	June 30, 2019		December 31, 2018

On December 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.	$	100,000	$	100,000

On November 26, 2018, the Company received proceeds of $100,000 from CSW on an unsecured promissory note due on demand that carries a 6% interest rate.		100,000		100,000

Total notes payable	$	200,000	$	200,000

Schedule of Interest Expenses

The Company recognized interest expense for the six months ended June 30, 2019 and the period from inception (March 27, 2018) to June 30, 2018, respectively, as follows:

	June 30, 2019		June 30, 2018

Interest on convertible notes	$	10,323	$	-
Interest on advances from shareholders		12,457		1,761
Interest on notes payable		5,951		-
Amortization of beneficial conversion features		125,000		-
Interest on accounts payable		1,965		40
Total interest expense	$	155,696	$	1,801

XML 41 R31.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of Components of Lease Expense

The components of lease expense were as follows:

	For the Six Months Ended
	June 30, 2019
Finance lease cost:
Amortization of assets	$	19,971
Interest on lease liabilities		9,158
Total lease cost	$	29,129

Schedule of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases were as follows:

	June 30, 2019
Finance lease:
Right-of-use asset	$	278,725
Accumulated amortization		(19,971	)
Right-of-use asset, net	$	258,754

Current portion of finance lease liability	$	38,561
Long-term finance lease liability		222,358
Total finance lease liability	$	260,919

Weighted average remaining lease term:
Operating leases		N/A
Finance leases		5.5 years

Weighted average discount rate:
Operating leases		N/A
Finance leases		6.75	%

Schedule of Supplemental Cash Flow Related to Leases

Supplemental cash flow and other information related to leases was as follows:

	For the Six Months Ended
	June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used for finance leases	$	26,964

Leased assets obtained in exchange for lease liabilities:
Total operating lease liabilities	$	-
Total finance lease liabilities	$	260,919

Schedule of Finance Lease Liability Maturity

The Company’s maturities of lease liabilities under finance leases as of June 30, 2019 are as follows:

	Finance
	Leases

2019	$	27,234
2020		55,824
2021		57,498
2022		59,223
2023		61,000
Thereafter		51,957
Total		312,876
Less interest		56,461
Present value of lease liabilities		260,919
Less current portion		38,561
Long-term lease liabilities	$	222,358

XML 42 R32.htm IDEA: XBRL DOCUMENT

Nature of Business and Significant Accounting Policies (Details Narrative)		3 Months Ended	6 Months Ended
	Feb. 21, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) Number
Proceeds from issuance convertible note \| $			$ 500,000
Number of operating segments \| Number			1
FDIC insured amount \| $			$ 250,000
Merger Agreement [Member]
Options to purchase common stock	825,000
Common stock exercise price \| $ / shares	$ 0.50
Merger Agreement [Member] \| OWP Ventures, Inc. [Member]
Number of stock issued	39,475,398
Options to purchase common stock	825,000
Common stock exercise price \| $ / shares	$ 0.50
Proceeds from issuance convertible note \| $	$ 300,000
Conversion price \| $ / shares	$ 0.424
Number of shares cancelled	875,000
Nature of business, description			As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future "Qualified Offering"; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures' chief operating officer became our chief operating officer and two of OWP Ventures' directors became members of our board of directors.

XML 43 R33.htm IDEA: XBRL DOCUMENT

Nature of Business and Significant Accounting Policies - Schedule of Common Control and Ownership Interest (Details)

6 Months Ended

Jun. 30, 2019

Name of Entity

One World Pharma, Inc.

One World Pharma, Inc [Member]

Name of Entity

One World Pharma, Inc

State of Incorporation

Relationship

Parent

^[1]

OWP Ventures, Inc. [Member]

Name of Entity

OWP Ventures, Inc.

State of Incorporation

Relationship

Subsidiary

^[2]

One World Pharma S.A.S. [Member]

Name of Entity

One World Pharma S.A.S.

State of Incorporation

Relationship

Subsidiary

^[3]

[1]	Holding company in the form of a corporation.
[2]	Holding company in the form of a corporation and wholly-owned subsidiary of One World Pharma, Inc.
[3]	Wholly-owned subsidiary of OWP Ventures, Inc. since May 30, 2018, located in Colombia and legally constituted as a simplified stock company registered in the Chamber of Commerce of Bogota on July 18, 2017. Its headquarters are located in Bogota.

XML 44 R34.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash on hand	$ 212,385	$ 125,846
Working capital deficit	745,796
Accumulated deficit	$ 4,608,726	$ 1,959,982

XML 45 R35.htm IDEA: XBRL DOCUMENT

Reverse Merger (Details Narrative) - USD ($)		3 Months Ended	6 Months Ended
Reverse Merger (Details Narrative) - USD ($)	Feb. 21, 2019	Jun. 30, 2018	Jun. 30, 2019
Proceeds from issuance convertible note			$ 500,000
Merger Agreement [Member]
Options to purchase common stock	825,000
Common stock exercise price	$ 0.50
Merger Agreement [Member] \| OWP Ventures, Inc. [Member]
Number of stock issued	39,475,398
Options to purchase common stock	825,000
Common stock exercise price	$ 0.50
Proceeds from issuance convertible note	$ 300,000
Conversion price	$ 0.424
Number of shares cancelled	875,000
Nature of business, description			As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future "Qualified Offering"; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures' chief operating officer became our chief operating officer and two of OWP Ventures' directors became members of our board of directors.

XML 46 R36.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 13, 2019	May 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Nov. 23, 2018	Oct. 25, 2018
Repayment of loan from related party		$ 207,000		$ 207,000
Advance from affiliates				$ 307,141	$ 514,141
Promissory Notes [Member]
Interest rate	6.00%
Debt principal amount	$ 307,141
Proceeds from private offering	$ 5,000,000
CEO [Member]
Advance from affiliates						$ 307,141	$ 307,141
Interest rate						6.00%	6.00%

XML 47 R37.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Schedule of Valuation of Financial Instruments at Fair Value on a Recurring Basis (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Level 1 [Member]
Cash	$ 212,385	$ 125,846
Right-of-use asset
Total assets	212,385	125,846
Convertible note payable
Advances from shareholders
Notes payable
Lease liability
Total liabilities
Total assets and liabilities	212,385	125,846
Level 2 [Member]
Cash
Right-of-use asset	258,754
Total assets	258,754
Convertible note payable
Advances from shareholders	307,141	514,141
Notes payable
Lease liability	260,919
Total liabilities	(568,060)	(514,141)
Total assets and liabilities	(309,306)	(514,141)
Level 3 [Member]
Cash
Right-of-use asset
Total assets
Convertible note payable	300,000	300,000
Advances from shareholders
Notes payable	200,000	200,000
Lease liability
Total liabilities	(500,000)	(500,000)
Total assets and liabilities	$ (500,000)	$ (500,000)

XML 48 R38.htm IDEA: XBRL DOCUMENT

Other Current Assets - Schedule of Other Current Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Security deposit	$ 4,518	$ 4,494
Prepaid expenses	67,350	30,850
Other receivables	64,911
Total	$ 136,779	$ 35,344

XML 49 R39.htm IDEA: XBRL DOCUMENT

Fixed Assets (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
Fixed Assets (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 103	$ 5,005

XML 50 R40.htm IDEA: XBRL DOCUMENT

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Fixed assets, gross	$ 720,898	$ 358,400
Less: accumulated depreciation	(6,966)	(1,961)
Total	713,932	356,439
Land [Member]
Fixed assets, gross	179,731
Office Equipment [Member]
Fixed assets, gross	23,469	18,314
Furniture and Fixtures [Member]
Fixed assets, gross	32,216	23,595
Software [Member]
Fixed assets, gross	17,654
Equipment and machinery [Member]
Fixed assets, gross	310,919
Construction in Progress [Member]
Fixed assets, gross	$ 156,909	$ 316,491

XML 51 R41.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued payroll	$ 53,681	$ 6,327
Accrued withholding taxes	6,232	6,387
Accrued ICA fees and contributions	11,936	8,514
Accrued interest	27,258	12,924
Deferred rent obligations		273
Accrued Expenses	$ 99,107	$ 34,425

XML 52 R42.htm IDEA: XBRL DOCUMENT

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended
Convertible Note Payable (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Debt discount		$ 125,000	$ 75,000
Finance expense		$ 125,000
Common stock percentage		4.99%
Interest expense		$ 10,323
Interest expense related to the debt discount		$ 125,000

XML 53 R43.htm IDEA: XBRL DOCUMENT

Convertible Note Payable - Schedule of Convertible Note Payable (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Less: unamortized debt discounts
Convertible note payable	300,000	300,000
Convertible Note Payable One [Member]
Convertible note payable, gross	300,000	300,000
Convertible Note Payable Two [Member]
Convertible note payable, gross

XML 54 R44.htm IDEA: XBRL DOCUMENT

Convertible Note Payable - Schedule of Convertible Note Payable (Details) (Parenthetical) - USD ($)			3 Months Ended	6 Months Ended
	Jan. 14, 2019	Nov. 30, 2018	Jun. 30, 2018	Jun. 30, 2019
Proceeds from convertible debt				$ 500,000
Convertible Note Payable One [Member]
Number of shares issued		875,000
Stock split ratio		1:4 split
Proceeds from equity securities		$ 500,000
Conversion price percentage		80.00%
Convertible Note Payable One [Member] \| CSW Ventures, LP [Member]
Proceeds from convertible debt		$ 300,000
Debt interest rate		6.00%
Convertible Note Payable Two [Member]
Proceeds from convertible debt	$ 500,000
Debt interest rate	6.00%
Proceeds from equity securities	$ 500,000
Conversion price percentage	80.00%
Debt maturity date	Jan. 14, 2022
Conversion price	$ 0.424
Debt converted into shares	1,253,493

XML 55 R45.htm IDEA: XBRL DOCUMENT

Advances from Shareholders (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2019
Related Party Transactions [Abstract]
Interest expense	$ 1,761	$ 12,457

XML 56 R46.htm IDEA: XBRL DOCUMENT

Advances from Shareholders - Schedule of Advances from Shareholders (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	May 03, 2018
Total advances from shareholders	$ 307,141	$ 514,141
Short-Term Unsecured Demand Loans One[Member]
Total advances from shareholders		514,141	$ 100,000
Short-Term Unsecured Demand Loans Two [Member]
Total advances from shareholders	$ 307,141

XML 57 R47.htm IDEA: XBRL DOCUMENT

Advances from Shareholders - Schedule of Advances from Shareholders (Details) (Parenthetical) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 13, 2019	May 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Nov. 23, 2018	Nov. 21, 2018	Nov. 09, 2018	Oct. 30, 2018	Oct. 25, 2018	May 29, 2018	May 14, 2018	May 03, 2018
Advance from affiliates				$ 307,141	$ 514,141
Repayment of loan from related party		$ 207,000		$ 207,000
CEO [Member]
Debt interest rate						6.00%				6.00%
Advance from affiliates						$ 307,141				$ 307,141
Short-Term Unsecured Demand Loans [Member]
Debt interest rate				6.00%
Advance from affiliates				$ 514,141		$ 50,000	$ 50,000	$ 50,000	$ 100,000	$ 57,141	$ 15,000	$ 82,000	$ 10,000
Short-Term Unsecured Demand Loans One[Member]
Advance from affiliates					$ 514,141								$ 100,000
Promissory Notes [Member]
Debt interest rate	6.00%
Debt principal amount	$ 307,141
Proceeds from private offering	$ 5,000,000

XML 58 R48.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2019
Interest expense		$ 10,323
Notes Payable [Member]
Interest expense		$ 5,951

XML 59 R49.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Total notes payable	$ 200,000	$ 200,000
Notes Payable One [Member]
Total notes payable	100,000	100,000
Notes Payable Two [Member]
Total notes payable	$ 100,000	$ 100,000

XML 60 R50.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - Unsecured Promissory Note [Member] - CSW Ventures, LP [Member] - USD ($)	Dec. 26, 2018	Nov. 26, 2018
Proceeds from notes payable	$ 100,000	$ 100,000
Debt interest rate	6.00%	6.00%

XML 61 R51.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Interest Expenses (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2019
Notes Payable - Schedule Of Interest Expenses
Interest on convertible notes				$ 10,323
Interest on advances from shareholders		1,761		12,457
Interest on notes payable				5,951
Amortization of beneficial conversion features				125,000
Interest on accounts payable		40		1,965
Total interest expense	$ 14,579	$ 1,801	$ 1,801	$ 155,696

XML 62 R52.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Components of Lease Expense (Details)	6 Months Ended
	Jun. 30, 2019 USD ($)
Leases [Abstract]
Finance lease cost: Amortization of assets	$ 19,971
Finance lease cost: Interest on lease liabilities	9,158
Total lease cost	$ 29,129

XML 63 R53.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)	Jun. 30, 2019 USD ($)
Leases [Abstract]
Finance lease: Right-of-use asset	$ 278,725
Finance lease: Accumulated amortization	(19,971)
Right-of-use asset, net	258,754
Current portion of finance lease liability	38,561
Long-term finance lease liability	222,358
Total finance lease liability	$ 260,919
Weighted average remaining lease term: Operating leases	0 years
Weighted average remaining lease term: Finance leases	5 years 6 months
Weighted average discount rate: Operating leases	0.00%
Weighted average discount rate: Finance leases	6.75%

XML 64 R54.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Supplemental Cash Flow Related to Leases (Details)	6 Months Ended
	Jun. 30, 2019 USD ($)
Leases [Abstract]
Operating cash flows used for finance leases	$ 26,964
Total operating lease liabilities
Total finance lease liabilities	$ 260,919

XML 65 R55.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Finance Lease Liability Maturity (Details)	Jun. 30, 2019 USD ($)
Leases [Abstract]
2019	$ 27,234
2020	55,824
2021	57,498
2022	59,223
2023	61,000
Thereafter	51,957
Total	312,876
Less interest	56,461
Present value of lease liabilities	260,919
Less current portion	38,561
Long-term lease liabilities	$ 222,358

XML 66 R56.htm IDEA: XBRL DOCUMENT

Changes in Stockholders' Equity (Details Narrative) - USD ($)									2 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended
	Feb. 21, 2019	Feb. 18, 2019	Feb. 08, 2019	Feb. 05, 2019	Feb. 04, 2019	Jan. 28, 2019	Jan. 10, 2019	Oct. 24, 2018	Feb. 19, 2019	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018
Common stock, shares authorized							75,000,000				75,000,000	75,000,000
Common stock, par value											$ 0.001	$ 0.001
Common stock, shares issued											39,922,899	34,291,905
Common stock, shares outstanding											39,922,899	34,291,905
Reverse stock split, description							1-for-4 reverse stock split
Cash received on subscriptions receivable											$ 602
Value common stock issued for debt conversion											501,397
Debt interest amount											10,323
Number of stock issued for services, value												$ 285,600
Options issued for service expense											560,958
Proceeds from issuance convertible note											$ 500,000
Merger Agreement [Member]
Options to purchase common stock	825,000
Common stock exercise price	$ 0.50
Consultant [Member]
Sale of stock price per share								$ 0.42
Number of stock issued for services								50,000
Number of stock issued for services, value								$ 21,000
OWP Ventures, Inc. [Member]
Common stock, par value				$ 0.001							$ 0.0001
Cash received on subscriptions receivable				$ 602
Number of stock sold									3,900,000
Sale of stock price per share									$ 0.50
Number of stock sold, value									$ 1,950,000
Number of stock issued for services		30,000
Number of stock issued for services, value		$ 15,000
Share issued price per share		$ 0.50
OWP Ventures, Inc. [Member] \| Merger Agreement [Member]
Number of stock issued	39,475,398
Options to purchase common stock	825,000
Common stock exercise price	$ 0.50
Proceeds from issuance convertible note	$ 300,000
Conversion price	$ 0.424
Number of shares cancelled	875,000
Nature of business, description											As a result of the Merger (a) holders of the outstanding capital stock of OWP Ventures received an aggregate of 39,475,398 shares of our common stock; (b) options to purchase 825,000 shares of common stock of OWP Ventures at an exercise price of $0.50 automatically converted into options to purchase 825,000 shares of our common stock at an exercise price of $0.50; (c) the outstanding principal and interest under a $300,000 convertible note issued by OWP Ventures became convertible, at the option of the holder, into shares of our common stock at a conversion price equal to the lesser of $0.424 per share or 80% of the price we sell our common stock in a future "Qualified Offering"; (d) 875,000 shares of our common stock owned by OWP Ventures prior to the Merger were cancelled; and (e) OWP Ventures' chief operating officer became our chief operating officer and two of OWP Ventures' directors became members of our board of directors.
OWP Ventures, Inc. [Member] \| Service Provider [Member]
Options to purchase common stock			100,000			500,000
Options exercise price			$ 0.50			$ 0.50
Number of options vested			8,333			41,666
OWP Ventures, Inc. [Member] \| Service Provider [Member] \| One-Year Anniversary [Member]
Number of options vested			8,337			41,674
OWP Ventures, Inc. [Member] \| Director [Member]
Options to purchase common stock			125,000
Options exercise price			$ 0.50
Number of options vested			10,416
OWP Ventures, Inc. [Member] \| Director [Member] \| One-Year Anniversary [Member]
Number of options vested			10,424
OWP Ventures, Inc. [Member] \| Service Provider One [Member]
Options to purchase common stock						100,000
Options exercise price						$ 0.50
Number of options vested						8,333
OWP Ventures, Inc. [Member] \| Service Provider One [Member] \| One-Year Anniversary [Member]
Number of options vested						8,337
Sanguine Group LLC [Member]
Number of common stock issued for debt conversion					1,253,493
Value common stock issued for debt conversion					$ 501,397
Debt principal amount					500,000
Debt interest amount					$ 1,397

XML 67 R57.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	6 Months Ended
Income Taxes (Details Narrative)	Jun. 30, 2019 USD ($)
Income Tax Disclosure [Abstract]
Federal net operating losses	$ 3,681,600
Net operating loss carry forwards, expire year	2038

XML 68 R58.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Aug. 12, 2019	Jul. 29, 2019	Jul. 17, 2019	Jul. 22, 2019
Number of stock sold	1,059,000	200,000	285,000
Sale of stock price per share	$ 0.50	$ 0.50	$ 0.50
Number of stock sold, value	$ 529,500	$ 100,000	$ 142,500
Two Outstanding Demand Notes [Member]
Interest rate				6.00%
Aggregate debt amount				$ 207,332
Principal amount				200,000
Accrued interest				$ 7,332
Convertible Promissory Notes [Member]
Interest rate				6.00%
Convertible promissory note				$ 207,332
Conversion price per share				$ 0.50

EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 132 322 1 true 40 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://oneworldpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://oneworldpharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://oneworldpharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://oneworldpharma.com/role/StatementsOfOperationsAndComprehensiveIncome Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Stockholders' Equity (Deficit) Sheet http://oneworldpharma.com/role/StatementOfStockholdersEquityDeficit Consolidated Statement of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://oneworldpharma.com/role/StatementOfCashFlows Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://oneworldpharma.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Reverse Merger Sheet http://oneworldpharma.com/role/ReverseMerger Reverse Merger Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://oneworldpharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value of Financial Instruments Sheet http://oneworldpharma.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 11 false false R12.htm 00000012 - Disclosure - Other Current Assets Sheet http://oneworldpharma.com/role/OtherCurrentAssets Other Current Assets Notes 12 false false R13.htm 00000013 - Disclosure - Fixed Assets Sheet http://oneworldpharma.com/role/FixedAssets Fixed Assets Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses Sheet http://oneworldpharma.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 00000015 - Disclosure - Convertible Note Payable Sheet http://oneworldpharma.com/role/ConvertibleNotePayable Convertible Note Payable Notes 15 false false R16.htm 00000016 - Disclosure - Advances from Shareholders Sheet http://oneworldpharma.com/role/AdvancesFromShareholders Advances from Shareholders Notes 16 false false R17.htm 00000017 - Disclosure - Notes Payable Notes http://oneworldpharma.com/role/NotesPayable Notes Payable Notes 17 false false R18.htm 00000018 - Disclosure - Leases Sheet http://oneworldpharma.com/role/Leases Leases Notes 18 false false R19.htm 00000019 - Disclosure - Changes in Stockholders' Equity Sheet http://oneworldpharma.com/role/ChangesInStockholdersEquity Changes in Stockholders' Equity Notes 19 false false R20.htm 00000020 - Disclosure - Income Taxes Sheet http://oneworldpharma.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 00000021 - Disclosure - Subsequent Events Sheet http://oneworldpharma.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) Policies http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) Sheet http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables Nature of Business and Significant Accounting Policies (Tables) Tables http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://oneworldpharma.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://oneworldpharma.com/role/FairValueOfFinancialInstruments 24 false false R25.htm 00000025 - Disclosure - Other Current Assets (Tables) Sheet http://oneworldpharma.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://oneworldpharma.com/role/OtherCurrentAssets 25 false false R26.htm 00000026 - Disclosure - Fixed Assets (Tables) Sheet http://oneworldpharma.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://oneworldpharma.com/role/FixedAssets 26 false false R27.htm 00000027 - Disclosure - Accrued Expenses (Tables) Sheet http://oneworldpharma.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://oneworldpharma.com/role/AccruedExpenses 27 false false R28.htm 00000028 - Disclosure - Convertible Note Payable (Tables) Sheet http://oneworldpharma.com/role/ConvertibleNotePayableTables Convertible Note Payable (Tables) Tables http://oneworldpharma.com/role/ConvertibleNotePayable 28 false false R29.htm 00000029 - Disclosure - Advances from Shareholders (Tables) Sheet http://oneworldpharma.com/role/AdvancesFromShareholdersTables Advances from Shareholders (Tables) Tables http://oneworldpharma.com/role/AdvancesFromShareholders 29 false false R30.htm 00000030 - Disclosure - Notes Payable (Tables) Notes http://oneworldpharma.com/role/NotesPayableTables Notes Payable (Tables) Tables http://oneworldpharma.com/role/NotesPayable 30 false false R31.htm 00000031 - Disclosure - Leases (Tables) Sheet http://oneworldpharma.com/role/LeasesTables Leases (Tables) Tables http://oneworldpharma.com/role/Leases 31 false false R32.htm 00000032 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) Sheet http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative Nature of Business and Significant Accounting Policies (Details Narrative) Details http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Common Control and Ownership Interest (Details) Sheet http://oneworldpharma.com/role/NatureOfBusinessAndSignificantAccountingPolicies-ScheduleOfCommonControlAndOwnershipInterestDetails Nature of Business and Significant Accounting Policies - Schedule of Common Control and Ownership Interest (Details) Details 33 false false R34.htm 00000034 - Disclosure - Going Concern (Details Narrative) Sheet http://oneworldpharma.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://oneworldpharma.com/role/GoingConcern 34 false false R35.htm 00000035 - Disclosure - Reverse Merger (Details Narrative) Sheet http://oneworldpharma.com/role/ReverseMergerDetailsNarrative Reverse Merger (Details Narrative) Details http://oneworldpharma.com/role/ReverseMerger 35 false false R36.htm 00000036 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://oneworldpharma.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://oneworldpharma.com/role/RelatedPartyTransactions 36 false false R37.htm 00000037 - Disclosure - Fair Value of Financial Instruments - Schedule of Valuation of Financial Instruments at Fair Value on a Recurring Basis (Details) Sheet http://oneworldpharma.com/role/FairValueOfFinancialInstruments-ScheduleOfValuationOfFinancialInstrumentsAtFairValueOnRecurringBasisDetails Fair Value of Financial Instruments - Schedule of Valuation of Financial Instruments at Fair Value on a Recurring Basis (Details) Details 37 false false R38.htm 00000038 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details) Sheet http://oneworldpharma.com/role/OtherCurrentAssets-ScheduleOfOtherCurrentAssetsDetails Other Current Assets - Schedule of Other Current Assets (Details) Details 38 false false R39.htm 00000039 - Disclosure - Fixed Assets (Details Narrative) Sheet http://oneworldpharma.com/role/FixedAssetsDetailsNarrative Fixed Assets (Details Narrative) Details http://oneworldpharma.com/role/FixedAssetsTables 39 false false R40.htm 00000040 - Disclosure - Fixed Assets - Schedule of Fixed Assets (Details) Sheet http://oneworldpharma.com/role/FixedAssets-ScheduleOfFixedAssetsDetails Fixed Assets - Schedule of Fixed Assets (Details) Details 40 false false R41.htm 00000041 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://oneworldpharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 41 false false R42.htm 00000042 - Disclosure - Convertible Note Payable (Details Narrative) Sheet http://oneworldpharma.com/role/ConvertibleNotePayableDetailsNarrative Convertible Note Payable (Details Narrative) Details http://oneworldpharma.com/role/ConvertibleNotePayableTables 42 false false R43.htm 00000043 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details) Sheet http://oneworldpharma.com/role/ConvertibleNotePayable-ScheduleOfConvertibleNotePayableDetails Convertible Note Payable - Schedule of Convertible Note Payable (Details) Details 43 false false R44.htm 00000044 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details) (Parenthetical) Sheet http://oneworldpharma.com/role/ConvertibleNotePayable-ScheduleOfConvertibleNotePayableDetailsParenthetical Convertible Note Payable - Schedule of Convertible Note Payable (Details) (Parenthetical) Details 44 false false R45.htm 00000045 - Disclosure - Advances from Shareholders (Details Narrative) Sheet http://oneworldpharma.com/role/AdvancesFromShareholdersDetailsNarrative Advances from Shareholders (Details Narrative) Details http://oneworldpharma.com/role/AdvancesFromShareholdersTables 45 false false R46.htm 00000046 - Disclosure - Advances from Shareholders - Schedule of Advances from Shareholders (Details) Sheet http://oneworldpharma.com/role/AdvancesFromShareholders-ScheduleOfAdvancesFromShareholdersDetails Advances from Shareholders - Schedule of Advances from Shareholders (Details) Details 46 false false R47.htm 00000047 - Disclosure - Advances from Shareholders - Schedule of Advances from Shareholders (Details) (Parenthetical) Sheet http://oneworldpharma.com/role/AdvancesFromShareholders-ScheduleOfAdvancesFromShareholdersDetailsParenthetical Advances from Shareholders - Schedule of Advances from Shareholders (Details) (Parenthetical) Details 47 false false R48.htm 00000048 - Disclosure - Notes Payable (Details Narrative) Notes http://oneworldpharma.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://oneworldpharma.com/role/NotesPayableTables 48 false false R49.htm 00000049 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://oneworldpharma.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 49 false false R50.htm 00000050 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://oneworldpharma.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 50 false false R51.htm 00000051 - Disclosure - Notes Payable - Schedule of Interest Expenses (Details) Notes http://oneworldpharma.com/role/NotesPayable-ScheduleOfInterestExpensesDetails Notes Payable - Schedule of Interest Expenses (Details) Details 51 false false R52.htm 00000052 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) Sheet http://oneworldpharma.com/role/Leases-ScheduleOfComponentsOfLeaseExpenseDetails Leases - Schedule of Components of Lease Expense (Details) Details 52 false false R53.htm 00000053 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) Sheet http://oneworldpharma.com/role/Leases-ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) Details 53 false false R54.htm 00000054 - Disclosure - Leases - Schedule of Supplemental Cash Flow Related to Leases (Details) Sheet http://oneworldpharma.com/role/Leases-ScheduleOfSupplementalCashFlowRelatedToLeasesDetails Leases - Schedule of Supplemental Cash Flow Related to Leases (Details) Details 54 false false R55.htm 00000055 - Disclosure - Leases - Schedule of Finance Lease Liability Maturity (Details) Sheet http://oneworldpharma.com/role/Leases-ScheduleOfFinanceLeaseLiabilityMaturityDetails Leases - Schedule of Finance Lease Liability Maturity (Details) Details 55 false false R56.htm 00000056 - Disclosure - Changes in Stockholders' Equity (Details Narrative) Sheet http://oneworldpharma.com/role/ChangesInStockholdersEquityDetailsNarrative Changes in Stockholders' Equity (Details Narrative) Details http://oneworldpharma.com/role/ChangesInStockholdersEquity 56 false false R57.htm 00000057 - Disclosure - Income Taxes (Details Narrative) Sheet http://oneworldpharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://oneworldpharma.com/role/IncomeTaxes 57 false false R58.htm 00000058 - Disclosure - Subsequent Events (Details Narrative) Sheet http://oneworldpharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://oneworldpharma.com/role/SubsequentEvents 58 false false All Reports Book All Reports owpc-20190630.xml owpc-20190630.xsd owpc-20190630_cal.xml owpc-20190630_def.xml owpc-20190630_lab.xml owpc-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 74 0001493152-19-012175-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-012175-xbrl.zip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�([IPL' M=M9\+"%[I93O.@G5*Z77:?6'L@>0Y.N&\76_U5$'#65KH<_)!=GU7@UO.K5- MM&^(1[_+K@KGG2W3;ZEY ^5UHZUPT$F6+6H'&^;
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end